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Historical concepts in tumor metastasis
Metastatic disease is one of the most important prognostic determinants and cause of death 
in cancer patients. The quest to recognize and unravel the mechanisms of how and why tumor 
cells home to and grow out in distant organs goes back to the time of Recarmier who in 1829 
recognized that cancer can spread from a primary tumor and coined the term “metastasis” 
from the Greek “methistemi” meaning ‘to change or displace’1. Virchow was in 1858 the first to 
hypothesize that metastasis takes place by the lodgement of tumor-emboli in the vasculature2. 
Some 30 years later Stephen Paget challenged this concept and stated that one remote organ is 
more prone to be the seat of secondary growth than another. In 735 autopsies of female breast 
cancer patients, he found 241 liver, 17 spleen and 30 kidney and adrenal gland metastases. The 
lungs were involved in 70 cases but lungs were not evaluated as remote organs but as locations 
with direct extension from the primary breast cancer. He showed a similar preference of uterus 
cancer to metastasize to different organs, with a distribution of 35 liver, 1 spleen, 8 lung, and 6 
kidney and adrenal metastases in 244 patients. In the same article Paget studied the occurrence 
of bone metastases. In 650 breast cancer patients the femur was affected in 18 patients, either 
by spontaneous fracture or distinct deposits of tumor, the humerus in 10 and the cranium in 36 
patients3.
He stated that there was more than only a mechanistic explanation needed for metastatic 
behavior of tumor cells, and argued that interactions between host and tumor cells are pivotal 
for metastatic outgrowth. He then proposed his famous seed and soil principle “When a plant 
goes to seed, its seeds are carried in all directions; but they can only live and grow if they fall on 
congenial soil.” According to this statement, for at least some cancer types distant niches exist 
that allow further development of cancer2-4. One of the most intensely studied relationships is 
that between prostate carcinoma and osteoclasts and osteoblasts in bone. Unique characteristics 
of the bone niche provide homing signals to these cancer cells and the biochemical (cytokines, 
growth factors) and physical (acidic pH, high extracellular calcium concentration) properties of the 
bone provide a microenvironment that is advantageous for the tumor cells which simultaneously 
influence osteoclast or osteoblast activity, resulting in bone breakdown or synthesis5.
Ewing challenged the statement of Paget in 1928 with the hypothesis that cancer cells are 
directed to the metastatic site via mechanistic means and through lymphatic and blood vessel 
systems6,7. Although some authors find this hypothesis in contradiction to Paget’s statement4 
others have explained it as a complementary step in the metastatic process. These authors 
subdivided migration into emigration (the act of leaving the primary tumor), migration (the act 
of travelling through stroma and vascular systems) and immigration (the process of arriving) and 
stated that the theory of Ewing was about the migration step and that of Paget was about the 
immigration step8.
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Recent concepts and developments in tumor metastasis with emphasis on invasion- 
independent metastasis
In the 1980’s Elizabeth Hay postulated a new biological concept explaining the initial emigration 
step which is now known as epithelial-mesenchymal-transformation (EMT). EMT was discovered 
in the primitive streak of chick embryos and allows a polarized epithelial cell, which normally 
interacts with basement membrane via its basal surface, to undergo multiple biological changes 
enabling it to acquire a mesenchymal cell phenotype. This mesenchymal phenotype is associated 
with enhanced migratory capacity, invasiveness, elevated resistance to apoptosis (anoikis) and 
production of extracellular matrix (ECM) components9. Later on the term was changed into 
epithelial-mesenchymal transition to emphasize its temporary nature10.
Mesenchymal-epithelial transition describes the reverse process. EMT is encountered in three 
distinct biological settings in which it has very different functional consequences. EMT type 1 
is developmental, type 2 is associated with fibrosis and wound healing and type 3 occurs in 
neoplastic cells11. It is generally agreed that during EMT epithelial cells show loss of cell-cell 
adhesion by losing E-cadherine expression, reorganization of the cytoskeleton via switching from 
keratin to vimentin intermediate filaments, loss of apical-basal polarity, acquisition of a spindle 
cell shape and increased motility allowing cells to invade in blood vessels12. This model is now 
considered to explain the early emigration phase of carcinoma cells (seeds).
Even though the initial events in tumor metastases can be explained by EMT, it does not explain 
the whole process. Indeed, patients whose blood contain high numbers of circulating tumor 
cells may develop no or only few metastases while the converse situation is also frequently 
observed13,14. Hanahan and Weinberg tried to classify the basic features common to all cancer 
types and defined these as self-sufficiency in growth signals, insensitivity to growth-inhibitory 
(antigrowth) signals, evasion of apoptosis, limitless replicative potential, avoidance of the immune 
system, sustained angiogenesis and tissue invasion and metastasis (Figure 1), and it is now clear 
that numerous ways exist by which metastatic tumor cells can interact with stromal elements15,16. 
Many other studies provided more insight in these complex relationships and its extrapolation to 
clinical tumors and treatment modalities17,18.
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Figure 1. Therapeutic Targeting of the Hallmarks of Cancer
Reprinted from Cell, Volume 144, Issue 5, Douglas Hanahan, Robert A Weinberg, Hallmarks of Cancer: The Next 
Generation, Pages 646-674, Copyright (2011), with permission from Elsevier
Drugs that interfere with each of the acquired molecular aberrations necessary for tumor growth 
and progression have been developed and are in clinical trials or in some cases approved for 
clinical use in treating certain forms of cancer. The drugs listed are only illustrative examples; there 
is a deep pipeline of candidate drugs with diff erent molecular targets and modes of action in 
development for most of these hallmarks.
Taken all information together, the process of metastasis can be subdivided in the following 
sequential steps: First, primary cancers develop as avascular masses which ultimately outgrow 
the blood vessel supply, leading to hypoxia which evokes an angiogenic response, ensuring 
vascularization of the neoplastic lesion. Growth factors such as TGF-beta (tumor growth factor- 
beta), derived from tumor stromal cells, induce EMT which allows individual cells to detach from 
the main tumor mass and to migrate through the tumor stroma and invade blood vessels. Upon 
entry in the circulation, cells that survive the harsh conditions of sheer stress, need to adhere to 
endothelial cells, extravasate and use signals from the metastatic site to grow out to a relevant 
lesion. This model is obviously highly generalized and every cancer type probably has its own 
specifi c adjustments.
1. Introduction
Al Mehdi et al showed in 2000 that Green Fluorescent Protein (GFP)-expressing HT1080 fibrosarcoma 
cells, a highly metastatic cell line derived from rat embryo fibroblasts transformed with rasH 
and myc oncogenes, attach to distant endothelial cells and proliferate intravascularly prior to 
infiltrating the perivascular stroma. This study is one of many that emphasizes the significance 
of cross-talk between tumor cells and stromal cells that is required in addition to the tumor cells’ 
own oncogenic signaling pathways for survival and tumor progression19. De Waal et al discussed 
the role of stroma in intravascular tumor emboli and how tumor cells have a survival advantage 
due to this relation20. In 2002 Sugino et al postulated an alternative hypothesis for hematogenous 
metastasis in a murine mammary tumor (MCH66) model of metastasis. MCH66 cells formed well-
demarcated tumors composed of small tumor nests (50 to 200 μm in diameter) surrounded by 
a continuous basement membrane, containing collagen type IV, laminin, and heparan sulfate 
proteoglycan. These nests were embedded in fibrous stroma which was highly vascularized. As 
the tumor grew, the neovessels developed into fused dilated sinusoidal structures and enveloped 
entire tumor nests, such that the tumor islands appeared to be entirely surrounded with blood. 
Tumor nests surrounded by endothelial cells were observed in the veins draining the tumor and 
in the pulmonary arterioles. Embolized tumor cells grew first intravascularly before extravasating 
into the lung parenchyma. The authors suggested that two biological activities are involved in 
the development of this sinusoidal vasculature; angiogenesis activity and vascular remodeling. 
In addition, they suggested that this model should prove useful in screening and development 
of new therapeutic agents for cancer metastasis21. In the following years new studies were 
published that described a comparable histology in human renal cell carcinoma, hepatocellular 
carcinoma, follicular thyroid carcinoma22,23 and more recently alveolar soft tissue sarcoma24. In one 
of these publications it was suggested that therapies that could destroy the embolus structures 
diminish the risk of dissemination22. The arising question about these tumors is how this particular 
angiogenic tumor phenotype develops and how invasion independent metastatic patterns are 
regulated within the hypoxia, VEGF and angiogenesis axis.
Role of hypoxia, VEGF and angiogenesis
Hypoxia is an important stimulus for Vascular Endothelial Growth Factor-A expression. Under 
normoxia, the oxygen-dependent proline hydroxylation of the hypoxia-inducible factors 
(HIF1-alpha and HIF2-alpha) takes place, resulting in binding to the Von Hippel Lindau gene 
product (pVHL)25-27. pVHL is part of a multiprotein complex, including E3 ubiquitin ligase28 
which ubiquitinylates HIFs that are subsequently rapidly removed from the cell via proteasomal 
degradation. The strict regulation of HIFs (with a half-life in the order of minutes) is important 
because HIFs are transcription factors which regulate the expression of a large number of genes, 
needed by the cell to cope with hypoxic stress (examples being vascular endothelial growth 
factor (VEGF)29, carbonic anhydrase IX (CA-IX) and glycolysis- associated enzymes). Hereditary 
VHL syndrome in which, among others, haemangioblastoma and clear cell renal cell carcinoma 
(ccRCC) are driven by loss of full VHL function due to a second hit or loss of heterozygosity 
resulting in accumulation of HIFs and a pseudo-hypoxic response, characterized by constitutive 
expression of genes involved in glycolysis and angiogenesis.
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Angiogenesis is defined as a new blood vessel sprouting from pre-existent vessels. The first 
description of sprouting angiogenesis in tumor growth was reported by Ausprunk and Folkman 
in 1977, which indicated the following steps; (1) The basement membrane is locally degraded 
on one side of the peritumoral postcapillary venule situated close to the angiogenic stimulus, 
(2) inter-endothelial contacts are weakened and endothelial cells migrate into the connective 
tissue, (3) a solid cord of endothelial cells form, (4) lumen formation occurs distal to the migrating 
front, contiguous tubular sprouts anastomose to form functional capillary loops, parallel with the 
synthesis of the new basement membrane and the recruitment of pericytes. They identified that 
blood vessel sprouting can initially progress without cell division, while sustained sprouting and 
further outgrowth requires proliferation30. Endothelial cells express vascular endothelial growth 
factor receptor-2 (VEGFR-2), a tyrosine kinase receptor that positively drives the mitogenic and 
chemotactic responses of endothelial cells to VEGF31.
In the 1970’s J. Folkman made the observation that in the absence of neovascularization, tumors 
cannot grow to sizes beyond 2-3 cubic millimeters32; this gave rise to a burst of angiogenesis 
research and laid the foundation for anti-angiogenic therapy. In 1971, Folkman proposed the 
concept of “anti-angiogenesis” as a modality in cancer therapy due to “the prevention of new 
vessel sprouts from penetrating into early tumor implant”.
Initiation of sprouting requires the specification of endothelial cells into tip and stalk cells bearing 
different morphologies and functional properties. Endothelial tip cells primarily migrate but 
proliferate only minimally in contrast to the endothelial stalk cells which do proliferate. In 2003 a 
new model was proposed in which the role of tip cells and stalk cells in sprouting angiogenesis 
was molecularly defined. Tip cells express high levels of VEGFR2 and Delta Like Ligand-4 (DLL4), 
are highly migratory and polarized and actively downregulate VEGFR2 expression on stalk cells 
via Notch signaling. Stalk cells proliferate during sprout extension and differentiate into nascent 
vascular lumen cells. Tip cell migration depends on a gradient of VEGF33. Among the human 
tumors VHL-mutated cancers such as clear cell renal cell carcinoma (ccRCC) are unique because 
the angiogenic response is not hypoxia-mediated, but is constitutively high due to continuous 
activation of the VEGF-A gene.
The most common type of kidney cancer is clear cell renal cell carcinoma (ccRCC) which arises 
in the cortex and constitutes about 90% of all newly diagnosed RCC34. The large majority of 
ccRCC cases are associated with functional loss of the Von-Hippel-Lindau (VHL) protein, through 
inactivating somatic or germline mutations, hypermethylation or chromosomal loss on 3p25.
Because of the morphological similarities we observed in our animal models with VEGF-A 
expressing subcutaneous tumors, we have chosen ccRCC as a clinical tumor model due to its 
constitutive VEGF-A production through functional loss of the Von-Hippel-Lindau (VHL) protein35,36 
to study the invasion independent metastatic pathway.
1. Introduction
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Renal cell carcinoma; epidemiology, genetics, classifications and therapeutic targets
Renal cell carcinoma (RCC) accounts for 3% of adult malignancies and constitutes 95% of renal 
tumors37. In the European Union, approximately 85 new cases and 35 deaths per 100,000 per year 
were reported38. RCC is one of the most aggressive urological cancers, with higher mortality-to-
incidence ratios than any other urological malignancy39. Complete resection remains the only 
curative treatment for RCC. More than 30% of the RCCs metastasize or recur after treatment 
for localized disease40. Up to 25-30% of the RCC patients have overt metastatic disease at initial 
presentation41.
Staging and grading of ccRCC
Just like many other cancers, renal tumors are classified using the TNM classification system with 
many revisions of this classification until recently42. The most important factor in the classifications 
is the tumor stage, including tumor diameter, perihilar invasion, perirenal invasion and invasion 
of/metastasis in the adrenal gland. For the N stage the number and the site of lymph node 
metastases is important. In addition to the TNM staging, the grading of the tumor is significant 
for prognosis. The historical Fuhrman grading was recently abandoned and replaced by the ISUP 
grading system where specific tumor morphology (sarcomatous and rhabdoid differentiation) 
results in higher grading of the individual tumors43.
VEGF Targeted therapy in ccRCC
ccRCC is one of the prototype human tumors for targeted therapy with anti-angiogenic drugs due 
to its high VEGF-A production and vascularity44. Angiogenesis, the formation of new blood vessels 
is one of the hallmarks for tumor growth and metastasis. The extensive studies on angiogenesis 
since the 1970’s have resulted in focusing on it as one of the most promising druggable targets 
in tumors45. Although the first expectation was that targeted therapy would turn these tumors 
into chronic disease, soon it became clear that there are more complex interactions with just 
transient effect of these medications46-48. There are some hypotheses on how antiangiogenic 
drugs work but the mechanism in humans is not clarified. Anti-angiogenic drugs have been used 
in the neoadjuvant setting for tumor downsizing in addition to their adjuvant use. In a recent 
prospective phase 2 trial in which 24 patients with locally advanced ccRCC were treated for 12 
weeks in a neo-adjuvant setting with axitinib (a multitarget inhibitor of VEGFR1, VEGFR2, VEGFR3, 
PDGFRB and c-KIT), the median tumor shrinkage was 28.3% according to RECIST criteria and 
statistically significant49.
Clinical trials in stage IV ccRCC with VEGF tyrosine kinase inhibitors (TKIs) and bevacizumab have 
shown significant improvements mainly in progression free survival (and lesser so in overall 
survival) and have led to the regulatory approval of these drugs for patients with stage IV RCC50. In 
a recent study, multivariate analysis demonstrated that the histological infiltrative growth pattern 
of the primary tumor compared to expansive growth pattern of the primary tumor was the only 
significant and independent parameter predictive of worse progression free survival in patients 
treated with Sorafenib51.
The effect of treatment on tumor size is mainly established via radiological imaging49. Alternatively, 
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uptake of radiolabeled compounds has been used as a measure of treatment efficacy (e.g. 111ln-
bevacizumab)52. There have been only few studies that directly investigated the effects of anti-
angiogenic compounds on histopathology. One study described TKI initiated vasculopathy in 
tumor vessels with necrosis and/degeneration in tumor tissue indicating antitumoral activity53.
The overall aim of this thesis was to study how constitutive expression of VEGF in cancers affects 
tumor phenotype in relation to metastatic behavior, and conversely, how anti-angiogenic 
treatment affects these processes.
Outline of this thesis
In chapter 1 we discuss the history of studies trying to give insight in different mechanisms of 
metastasis with emphasis on the seed and soil hypothesis, epithelial-mesenchymal transformation 
and angiogenesis and how these mechanisms can be related to each other.
In chapter 2 the effects of VEGF-A expression on tumor phenotype and metastatic behavior in a 
model of subcutaneous melanoma are studied, using isogenic xenograft pairs producing VEGF-A 
or not. We also investigate the effects of inhibition of VEGF effects in these models.
Chapter 3 demonstrates histological ex vivo proof for the existence of a VEGF-A induced 
invasion-independent metastatic pathway in clinical ccRCC and provides circumstantial evidence 
that tumor cell clusters can escape from primary ccRCCs that are captured in the pulmonary 
vasculature where they grow out as pulmonary metastases.
Chapter 4 shows the deleterious effects of the neoadjuvant anti-angiogenic therapy on ccRCC 
morphology and the unexpected increase in the escape of tumor cell clusters resulting in worse 
prognosis in patients with metastatic disease.
Chapter 5 demonstrates the differences in response to 1-week anti-angiogenic treatment 
in a case of ccRCC harboring a low grade ccRCC and high grade (rhabdoid) component with 
differences in VEGF-A content, low- versus- high respectively.
Chapter 6 describes development of an unusual pulmonary lymphangitis carcinomatosa 
metastatic phenotype in a ccRCC patient by whom the metastasis initially responded to anti- 
angiogenic therapy and showed downsizing. Our observations suggest that pulmonary 
metastasis of ccRCC can respond to anti-angiogenic therapies by adopting a diffuse phenotype 
that allows progression in an angiogenesis-independent way.
Chapter 7 gives a summary of the conducted studies in this thesis, the initial expectations from 
the studies, what we learned from the results and how these result can have an influence on 
future studies.
1. Introduction 
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Abstract
How and why tumors metastasize is still a matter of debate. The assumption is that mutations 
render tumor cells with a metastatic phenotype, enabling entrance in and transport through 
lymph or blood vessels. Distant outgrowth is thought to occur only in a suitable microenvironment 
(the seed and soil hypothesis). However, the anatomical location of most metastases in cancer 
patients suggests entrapment of tumor cells in the first microcapillary bed that is encountered. 
We here investigated how vascular endothelial growth factor-A (VEGF-A) attributes to the 
metastatic process. We describe here that VEGF-A enhances spontaneous metastasis by inducing 
intravasation of heterogeneous tumor cell clusters, surrounded by vessel wall elements, via an 
invasion-independent mechanism. These tumor clusters generate metastatic tissue embolisms 
in pulmonary arteries. Treatment of tumor-bearing mice with the antiangiogenic compound 
ZD6474 prevented the development of this metastatic phenotype. This work shows that tumors 
with high constitutive VEGF-A expression metastasize via the formation of tumor emboli and 
provides an alternative rationale for anti-VEGF-A therapy, namely to inhibit metastasis formation.
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Introduction
Most cancer patients die from complications that result from metastases, rather than from 
a primary tumor. Lung metastasis is a most feared complication of a significant proportion of 
cancers, for example mamma carcinoma, renal cell carcinoma and head and neck tumors. The 
exact mechanisms of metastasis are still matter of debate. The current hypothesis is that tumor 
cells accumulate mutations that result in a metastatic phenotype, characterized by the capacity 
to invade blood and lymph vessels1. After transport, cells adhere to endothelium, extravasate or 
grow intravascularly2 and then grow to clinically relevant lesions at distant sites, provided that 
these sites constitute a suitable niche (the seed and soil hypothesis)3. It was recently described 
that such niches can also be prepared by bone marrow-derived cells to allow metastatic growth4.
Although it is well known that expression of vascular endothelial growth factor-A (VEGF-A) and 
the concomitant increase in vessel density correlates with poor prognosis in a number of tumor 
types5-7, the mechanism behind this correlation is also not exactly understood, although several 
explanations may be applicable: tumor cells that secrete VEGF-A may be more successful in 
outgrowing its dormant state after metastatic deposition1,8. Also, the probability of tumor cell 
entry into the blood is expected to increase with vessel density.
Yet, there are arguments against both explanations. First, clinical and animal data show that for 
metastatic tumors in brains, lungs or livers, induction of angiogenesis is not a prerequisite as 
for these tumors the pre-existent vascular bed may allow tumor growth2,9-15. Secondly, recent 
reports demonstrated the presence of intravascular endothelium-covered tumor cell clusters in 
the primary tumor as origin of metastasis16-18. Clinical and preclinical data suggest that not the 
amount of circulating single tumor cells but rather that of circulating tumor cell clusters correlate 
with development of metastases19-22. At this moment it is not clear whether these clusters have 
a single cell origin or are derived from tumor cell aggregates that dissociated from the primary 
tumor and intravasated as such. Support for the latter hypothesis comes from studies showing 
that spontaneous metastases derived from genetically polyclonal tumors were, at least in part, 
also polyclonal23.
Most investigations in the field of metastasis have been performed using colonization approaches 
in which tumor cells are hematogenously directed to the organs of interest24,25. These colonization 
models lack the initial event of tumor cell entry into the blood stream, an important and possibly 
rate-limiting step. Here we investigated which steps of the metastatic process are influenced by 
VEGF-A.
Results
VEGF-A does not increase metastatic burden in colonization assays
To investigate whether VEGF-A enhanced brain colonization by Mel57, a human melanoma 
cell line with low to undetectable levels of endogenous VEGF-A26, we injected a 1:1 mixture of 
Mel57-VEGF-A cells and Mel57-enhanced green fluorescent protein (EGFP) cells (serving as VEGF-
A-negative control cells) into the internal carotid artery of nude mice and analysed numbers 
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and composition of brain lesions by anti-EGFP immunostaining and in situ hybridization (ISH) 
for VEGF-A. More than 85% of the lesions grew by clonal expansion as they consisted of either 
Mel57-EGFP cells or Mel57-VEGF-A cells (Figure 1a, upper two panels and Figure 1b). There was 
no significant difference between numbers of EGFP- and VEGF-A-expressing lesions (Figure 1b), 
ruling out a stimulatory effect of VEGF-A in this colonization model. These data were confirmed 
in a second colonization assay, in which a mixture of Mel57-VEGF-A and Mel57-EGFP cells was 
injected into the tail vein. Again, tumors developed in brain predominantly by clonal expansion 
of single tumor cells (Figure 1c). Remarkably, although multiple lesions developed in the brains 
of these animals, no or only few lung lesions were detected, indicating a strong preference of the 
melanoma cells for brain parenchyma.
Figure 1. VEGF-A expression does not facilitate colonization potential in brain upon intracarotid or 
intravenous injection. (a) EGFP immunostaining of brain lesions consisting of Mel57-EGFP, Mel57-VEGF-A 
or a mixture as indicated. Bar represents 0.2mm. (b) Quantification of monoclonal and polyclonal 
lesions in brain after intracarotid injection of a 1:1 mixture of VEGF-A and EGFP cells. Note that VEGF-A 
did not enhance homing to brain (n=11). More than 85% of the lesions were homogeneous and thus 
were likely to have a monoclonal origin. (c) Quantification of tumor types in brain after intravenous 
injection into the tail vein (n=7). Again, brain lesions had a predominantly monoclonal origin.
Morphology of subcutaneous tumors: VEGF-A-induced micronodular transformation
Mel57-EGFP and Mel57-VEGF-A subcutaneous tumors were characterized on the morphological 
and immunohistochemical level. Parental Mel57 and Mel57–EGFP tumors behaved similarly 
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with respect to growth rate (not shown) and had comparable phenotypes. They developed 
relatively slowly and were highly necrotic (Figure 2a), leaving a small rim of viable tumor tissue 
that was sparsely vascularized (Figure 2d). A completely different growth rate and architecture 
was observed with Mel57-VEGF-A xenografts. These grew rapidly to large, histologically viable-
appearing tumors with a distinct morphology (Figure 2b and c, e– i). Tumors were composed 
of multiple micronodules that were surrounded by a network of laminin, endothelial cells and 
pericytes (Figure 2e–i, see also Figure 4g). Some of these (smaller) nodules were protruding in 
large sinusoidal vessels (Figure 2c, e, g and respective insets). A double staining for α-smooth 
muscle actin (α-SMA) and CD34 revealed a composition in which the pericytes were located on 
the inside, whereas endothelial cells were at the outer edge (Figure 2i). This is consistent with a 
model of bulging of micronodules into dilated vessels during which process nodules become 
gradually covered by vessel wall elements as previously suggested17. Sometimes, small nodules in 
the tumor periphery appeared only loosely, if at all, attached to the vessel wall and impressed as 
tumor emboli. Instead of widespread central necrosis, as observed in parental Mel57 xenografts, 
the larger individual tumor nodules in the tumor center showed small areas of central necrosis 
(compare Figure 2b and a).
Figure 2. Histological architecture of Mel57-EGFP and Mel57-VEGF-A. (a–c) H&E staining. (d and e) Anti-CD34 
staining. Note the micronodular structure of the VEGF-A tumor and the coverage of these nodules by pericytes 
and endothelial cells ( SMA staining in (g) and CD34 staining in (e). The endothelial identity was confirmed by 9F1 
staining (f) and CD31 (h). Figure i shows a double staining, in which endothelial cells are stained with anti- CD34 
and developed with fast blue (arrow), whereas pericytes are visualized in red (via anti-SMA-staining, arrowhead). 
Note that endothelial cells were localized primarily at the outer side of the nodules, whereas pericytes were on the 
inside. Frequently, loose nodules were observed in dilated sinusoidal vessels (c, e, g, and insets). In contrast, Mel57 
tumors were highly necrotic in the tumor center (a). Only the tumor rim consisted of viable cells with few vessels (a 
and d). Bars represent: 1 mm in (a–e and g) 0.1 mm in (f, h and 0.2 mm in i).
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VEGF-A enhances metastasis in a spontaneous metastasis model
To examine whether VEGF-A increased the efficiency of metastasis, Mel57-EGFP and Mel57-
VEGF-A xenografts were grown on opposite flanks of the same mice. On the basis of growth 
curves of individual tumors (not shown), we injected the Mel57-EGFP tumors 5 weeks before 
injection of Mel57-VEGF-A tumors to compensate for the difference in tumor growth rates. Mice 
were killed when EGFP and VEGF-A tumors had reached similar sizes (Figure 3a) and metastatic 
burden and composition of the lesions were analysed by anti-EGFP immunostaining and VEGF-A 
mRNA ISH. VEGF-A expression significantly increased the probability of lung metastasis formation. 
More than 90% of lung lesions were derived from the Mel57-VEGF-A xenografts (P=0.043, Figure 
3b). Tumors were always localized within the larger branches of pulmonary arteries (Figure 3c, 
arrows), strongly suggesting that these originated from tumor embolisms. Interestingly, despite 
the strong preference of the Mel57 cells for brain, which was apparent from the intravenous 
colonization assays, brain metastases were never detected in mice carrying subcutaneous Mel57 
xenografts.
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Figure 3. VEGF-A enhances spontaneous metastasis from subcutaneous tumors. (a) Growth curves of EGFP 
(– –) and VEGF-A (... ...)-expressing Mel57 tumors, grown on the opposite flanks of mice (n=5). After 9 weeks, 
when tumors had reached similar sizes, mice were killed (see text). Tumor growth was measured weekly using 
calipers. Tumor volumes are expressed as height x width x depth. The dip in the growth curve at day 45 is caused 
by the excision of Mel57-EGFP tumors in two mice due to ulceration. These mice were included in the analysis 
of composition of metastasis. (b) Lung lesions, consisting of Mel57-VEGF-A or Mel57-EGFP cells were counted 
after EGFP immunostaining. To confirm identity of VEGF-A lesions, VEGF mRNA-ISH was performed (not shown). 
(c) Representative H&E staining, showing tumor emboli located in the larger branches of the pulmonary arteries 
(arrows). Bar represents 0.3 mm.
VEGF-A-induced micronodular growth facilitates the formation of multicellular tumor 
emboli
To examine in more detail the composition of the tumor emboli in the lungs, we injected 
a 1:1 mixture of Mel57-EGFP and Mel57-VEGF-A cells into the flank of nude mice to establish 
mixed subcutaneous tumors. The resulting xenografts showed comparable growth profiles and 
phenotypes as Mel57-VEGF-A xenografts (see hematoxylin and eosin (H&E) staining in the inset 
in Figure 4a). The composition of most lung deposits was polyclonal with both Mel57- EGFP and 
Mel57-VEGF-A cells, very similar to the micronodules in the primary tumors (EGFP stainings in 
Figure 4a, b and VEGF-A ISH in Figure 4h). VEGF-A ISH and EGFP stainings were complementary 
(not shown), indicating that transgenic proteins were stably expressed and that no confounding 
loss of expression had occurred. Only a small fraction of the lesions was clonal, containing either 
Mel57-EGFP or Mel57-VEGF-A cells (Figure 4l). This reflected the composition of the primary tumors 
where occasionally nodules were found that consisted of a single-cell type, probably also arising 
by clonal expansion within the primary tumor (Figure 4c, arrowheads). Interestingly, in the right 
ventricle of one tumor- bearing animal, we found micronodules of the same mosaic composition 
as the primary tumor and the lung lesions (Figure 4d and inset). Again, these nodules had tissue 
characteristics as they contained laminin (Figure 4e) and were covered by proliferating mouse 
stromal cells (Figure 4f: Ki67 staining, Figure 4g: α α-SM staining). The presence of heterogeneous 
tumor noduli in the circulation was consistent with the presence of similar heterogeneous tumor 
fragments, lying almost loose in peritumoral-dilated vasculature (Figure 4m).
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Figure 4. Analysis of VEGF-A-induced metastatic tissue. Subcutaneous mixed tumors containing equal numbers 
of Mel57-EGFP and Mel57-VEGF-A cells were grown on the flanks of nude mice (n=14). (a) EGFP staining of a 
subcutaneous mixed tumor and (b) a lung lesion from the same animal. The inset in (a) shows an H&E overview 
field (x 25) of the same tumor, showing the nodular phenotype that is characteristic of Mel57-VEGF-A tumors. Note 
the similar composition of lung lesions in (b) and subcutaneous tumor micronodules. (c) In the primary tumor, 
regions with a homogeneous composition could be identified (arrow), consistent with the occurrence of small 
numbers of homogenous lung lesions (l). (d) EGFP staining of tumor micronodules in the right ventricle of the 
heart. Immunostaining showed that nodules were covered by laminin (e), proliferating (f) endothelial cells and 
pericytes (g), giving these nodules tissue characteristics. Note that in f, only murine proliferating cells are detected 
with our antibody. To confirm VEGF-A identity of EGFP-negative Mel57 cells, VEGF-A ISHs on lung lesions were 
performed (h); sense control hybridization (k). Bars represent 0.2 mm. (l) Quantification in lungs of mono- and 
polyclonal metastases, derived from mixed subcutaneous xenografts (see also Table 4). (m) intravascular nodule, 
derived from a VEGF-A/EGFP mixed tumor with a polyclonal composition, as illustrated by EGFP- immunostaining. 
Note that the nodule is almost loose within the vasculature.
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ZD6474 prevents formation of the metastatic phenotype
We treated Mel57-VEGF-A xenografts with 50 mg/kg ZD6474, a tyrosine kinase inhibitor which 
targets VEGFR2 and the epidermal growth factor receptor (EGFR)27, starting at day 8 post tumor 
cell inoculation, when small tumors were already visible. Further outgrowth of xenografts was 
effectively inhibited as compared to tumors in placebo-treated animals (Figure 5a). (Immuno)
histological analysis after 27 days of therapy revealed small tumors with large necrotic areas. 
Interestingly, treated tumors still presented with a nodular phenotype, but the nodules lacked 
coverage by activated endothelial cells (compare CD34 stainings in Figure 5b and c). No 
metastases were found in treated mice (n=5), in contrast to the placebo controls (mean 16, 
range 4–29, n=18). When treatment was started 4 weeks post-inoculation, metastatic burden was 
not reduced as compared to placebo treatment. These results suggest that metastatic emboli 
escape the tumor during early stages of tumor growth. Furthermore, they show that ZD6474 
treatment does not inhibit metastatic outgrowth in lungs, possibly reflecting the potential to 
grow by cooption in highly vascularized tissues13,28. Furthermore, the intravascular localization 
of these metastases, very near to air-filled alveoli, may enable tumor growth without additional 
angiogenesis.
Discussion
Tumor dissemination is a complex multistep process, requiring migration through matrix, 
intravasation, transport, extravasation and outgrowth. Interactions between tumor and stromal 
cells at distant sites are eminently important and metastatic niches may be prepared by bone 
marrow-derived cells4. Tumor dissemination to liver and lungs may differ from that to other parts 
in the body, because the microcapillary beds in these organs act as passive filters, trapping tumor 
cells or tumor fragments. Thus, metastasis may also be looked at as a passive event in which 
tumor cells or clusters are trapped in pulmonary arterioles or capillaries and grow intravascularly 
before breaking through the vessel wall and spreading further2.
Expression of VEGF-A by tumors and concomitant high tumor vessel densities have been 
associated with poor prognosis in a number of cancer types5,29, supposedly owing to an increased 
chance of tumor cell intravasation. However, correlations between high vessel densities and 
numbers of circulating tumor cells have never been established although the presence of 
circulating tumor cell clusters does correlate with prognosis21,22. In our brain colonization models 
of mixed Mel57-VEGF-A/Mel57-EGFP cell populations, metastases developed predominantly by 
clonal outgrowth of single cells, which is in agreement with observations by others30. Interestingly, 
upon injection of Mel57 cells into the tail vein, multiple brain lesions but only few lung lesions 
developed, indicating a clear preference of this cell line to colonize brain (compatible with the 
‘seed and soil’ hypothesis3). In these assays, VEGF-A did not increase tumor burden in brains, 
consistent with previous reports31. In contrast, Mel57-VEGF-A subcutaneous tumors metastasized 
to lungs much more efficiently than Mel57-EGFP tumors. In fact, the VEGF-A effects may have 
been underestimated because Mel57-VEGF-A tumors had 5 weeks less time to metastasize than 
the Mel57-EGFP xenografts. Altogether, these data suggest that VEGF-A exerts its effect on the 
level of tumor cell intravasation.
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Our results show convincingly that VEGF-A-expressing tumor cells detached from the primary 
tumor as tissue fragments, covered by vessel wall elements. These fragments entered the 
circulation, were captured in the lung capillary bed and grew out, initially intravascularly. This 
model is consistent with the presence of micronodules in the circulation such as in a right heart 
ventricle and in peritumoral-dilated vasculature in the xenografts. Such nodules were observed 
only occasionally, which is expected as these are carried away by the circulation instantly, similar 
to the model proposed by Sugino et al17.
Thus, VEGF-A induces a passive metastatic phenotype that results in dissemination to lung. How 
does this phenotype evolve? It appears from our data that endothelial cells and pericytes in dilated 
vasculature are induced by tumor-derived VEGF-A to proliferate and migrate, thus covering up 
the micronodules that gradually protrude into the lumen of these vessels. This scheme of events 
would indeed predict the observed topology of endothelial cells and pericytes on nodules. 
Tumor nodules that are located suboptimally for intravasation will remain localized and grow out 
to make up the main tumor mass.
Our data provide an explanation for the lack of correlation between circulating tumor cells and 
prognosis22: PCR-based techniques on blood samples do not distinguish between tumor cell 
clusters with metastatic capacity and single circulating tumor cells that may not be able to survive 
because they are not in a ‘tumor-tissue’ context. It is also tempting to speculate that coverage by 
endothelial cells leads to protection from the immune system, thus further increasing the chance 
of successful metastatic deposition.
Our study places an important footnote to the prevailing view that metastases arise by clonal 
outgrowth of single tumor cells that have acquired a metastatic phenotype24,30,32. In fact, tumor 
cells like Mel57-EGFP that metastasize inefficiently, can successfully travel along with VEGF-A-
expressing tumor cells. This may explain the occasional presence in cancer patients of metastases 
that have little angiogenic potential although they originated from highly angiogenic primary 
tumors33.
Tumor tissue fragments may have high clinical relevance as these are frequently found in lymph 
and blood vessels of cancer patients with poor prognosis34,35. Interestingly, renal clear cell 
carcinomas, which frequently show constitutive VEGF-A expression, also frequently display a 
nodular phenotype and intravascular growth18. Clearly, VEGF-A does not always induce metastatic 
dissemination36,37. The effect of VEGF-A that we describe here may be tumor specific to a certain 
extent. In a mouse model of metastatic mammary carcinoma, metastatic potential was attributed 
to pleiotrophin16,17. An exclusive role for this protein in our tumors can be excluded as this factor 
is also expressed in parental Mel57 cells38. E-cadherin has been described to be essential for 
intercellular tumor cell adhesion in circulating tumor cell clusters39,40. In our model, however, 
neither the parental nor the VEGF-A tumors expressed E-cadherin (unpublished results).
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Anti-VEGF therapy is considered to be a valuable approach to prevent clinical manifestations 
of metastatic disease in cancer patients. By inhibiting angiogenesis, minute metastatic deposits 
should remain dormant, turning cancer into a chronic disease. However, the angiogenesis 
dependency of tumors in vessel-dense organs may be not strict because tumors may incorporate 
pre-existent vasculature28,41. Our results point to a possible novel role for antiangiogenic therapy: 
anti-VEGF therapy in patients with primary cancers might decrease the chance of metastatic 
spread, not simply by decreasing vascular density, but rather by preventing the formation of 
metastatic tissue. Whether such application will have future relevance remains to be seen, as 
patients with primary tumors are generally no candidates for anti-VEGF therapies.
Figure 5. ZD6474 treatment of Mel57-VEGF xenografts. Two million tumor cells were injected in the flank of nude 
mice, and after 8 days daily treatment with 50 mg/kg ZD6474 (n=5) or placebo control (n=5) was started. At day 
37, animals were killed and tumors and lungs were analysed. (a) Growth curve of tumors, showing that tumor 
outgrowth is highly repressed by the VEGFR2 inhibitor. (b) CD34 endothelial cell staining of control-treated tumor 
(c) CD34 staining of ZD6474-treated tumor. Note the almost complete lack of activated endothelial cells in (c), 
although an overall micronodular phenotype can be observed.
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Materials and methods
Animals
Specific pathogen-free male (SPF), 6-8-week-dd old BALB/c nu/nu mice were housed under SPF 
conditions (five mice/cage, temperature 20–24°C; relative humidity 50–60%; 15 air changes per 
hour; light–dark periods 14 h/10 h). Water and food were available to the animals ad libitum. 
Experiments were carried out in accordance with the national animal protection laws.
ZD6474 treatment
A suspension of ZD6474 in 0.5% Tween-80 was given daily by oral gavage at a dose of 50 mg/
kg. Treatment was initiated 8 days post-injection of tumor cells, when tumors had grown to 
approximately 100 mm3 or after 4 weeks. Tumors were measured twice weekly with calipers, 
and tumor volumes were expressed as height x depth x width. Mice were killed at day 45, and 
analysed for tumor composition and lung metastasis.
Cell lines and transfections
Stable transfectants of Mel57-expressing EGFP and VEGF-A165 were described elsewhere11. 
VEGF-A expression levels in conditioned media were determined by enzyme-linked 
immunosorbent assay as described previously42 and were 30–50 ng/106 cells/24 h in the VEGF-A 
transfectants and <10 pg VEGF/106 cells/24 h in the EGFP transfectants. There was no difference 
between growth rates of the different cell lines in vitro (not shown).
Colonization and metastasis models 
Colonization models
Equal numbers (5 x 104) of Mel57-VEGF-A and Mel57-EGFP cells were coinjected into the internal 
carotid artery for induction of brain metastases as described (n=11)11,43. Similarly, 6x106 Mel57-
VEGF and Mel57-EGFP cells (in a 1:1 ratio) were injected into the tail vein of nude mice (n=7) to 
examine homing to lung and brain. Animals were killed after 2–3 weeks when mice developed 
cachexia or acute neurological defects.
Spontaneous metastasis
Subcutaneous tumors were induced in nude mice by injection of a mixture of Mel57-VEGF-A 
and Mel57-EGFP cells into the flank (1x106 cells for each cell line, n=9). In a second experiment, 
a Mel57-EGFP tumor was grown on the right flank and a Mel57-VEGF-A tumor on the left flank 
(2x106 cells per flank) (n=5). Mel57-EGFP cells were injected 5 weeks before Mel57-VEGF-A cells to 
ensure that both tumors were of comparable size at the time of analysis.
Mice were killed after development of severe cachexia owing to tumor load. In two out of five 
animals carrying tumors on both flanks, Mel57-EGFP tumors had to be removed because of 
severe ulceration after 6 weeks of tumor growth. These mice were still included in the analysis of 
metastatic composition.
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Histological and immunohistochemical analysis
For (immuno)histochemistry, 4 μm sections of formalin-fixed and paraffin-embedded tissues 
(subcutaneous tumor, heart, lung and/or brain) were treated as described before11,38. Antibodies 
were anti-EGFP (a kind gift of Dr E Cuppen, Department of Cell Biology, University Nijmegen 
Medical Center, The Netherlands), anti-mouse CD34 (Hycult Biotechnology, Uden, The 
Netherlands), rabbit anti-mouse Ki-67 (Dianova, Hamburg, Germany), mouse anti-α-SMA (α-
Sm1, Sigma, Zwijndrecht, The Netherlands) and rabbit anti-laminin (Dako, Glostrup, Denmark). 
To detect Mel57-VEGF-A cells, we performed ISH on 10 μm sections using a digoxigenin-labeled 
VEGF-A antisense RNA as probe and the corresponding sense RNA as a control, using standard 
techniques.
Double stainings for CD34 and α-Sm1 were performed on 4 μm sections of paraffin- embedded 
tumors as follows. After deparaffinization and rehydration, endogenous peroxidase was blocked 
by a 30-min incubation in 3% hydrogen peroxide in phosphate-buffered saline (PBS). After rinsing 
in PBS (three times for 5 min each), the sections were boiled in citrate buffer (10 mM, pH 6.0) for 
antigen retrieval. After blocking, sections were incubated overnight at 4°C with the rat monoclonal 
CD 34 primary antibody that was subsequently visualized by subsequent incubations with a 
biotinylated secondary anti-rat antibody and alkaline phosphatase (AP)-conjugated avidin. AP 
was developed with Fast Blue.
After that sections were blocked again and incubated overnight at 4°C with the α-SMA antibodies. 
These were visualized by horseradish peroxidase (HRP)-labeled secondary antibodies and AEC 
reagent, resulting in a red staining.
Statistical analysis
In each mouse, the number of microscopic lesions consisting of EGFP- or VEGF-A- expressing cells 
and mixed lesions were counted. From these numbers, ratios of monoclonal/polyclonal lesions 
were calculated. For subcutaneous tumors, volumes were determined by multiplying height x 
width x depth. The softwareprogram SPSS (SPSS 9.0 for Windows, SPSS Inc., Chicago, IL, USA) was 
used for statistical analysis. Differences were considered significant when P<0.05, as determined 
by Wilcoxon-signed rank test. Analyses were performed both on absolute numbers and ratios, 
where appropriate.
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Abstract
Tumour metastasis is the result of a complex sequence of events, including migration of tumour 
cells through stroma, proteolytic degradation of stromal and vessel wall elements, intravasation, 
transport through the circulation, extravasation and outgrowth at compatible sites in the body 
(the ‘seed and soil’ hypothesis). However, the high incidence of metastasis from various tumour 
types in liver and lung may be explained by a stochastic process as well, based on the anatomical 
relationship of the primary tumour with the circulation and mechanical entrapment of metastatic 
tumour cells in capillary beds. We previously reported that constitutive VEGF-A expression 
in tumour xenografts facilitates this type of metastatic seeding by promoting shedding of 
multicellular tumour tissue fragments, surrounded by vessel wall elements, into the circulation. 
After transport through the vena cava, such fragments may be trapped in pulmonary arteries, 
allowing them to expand to symptomatic lesions. Here we tested whether this process has 
clinical relevance for clear cell renal cell carcinoma (ccRCC), a prototype tumour in the sense 
of high constitutive VEGF-A expression. To this end we collected and analysed outflow samples 
from the renal vein, directly after tumour nephrectomy, in 42 patients diagnosed with ccRCC. 
Tumour fragments in venous outflow were observed in 33% of ccRCC patients and correlated 
with the synchronous presence or metachronous development of pulmonary metastases (p < 
0.001, Fisher’s exact test). In patients with tumours that, in retrospect, were not of the VEGF-A- 
expressing clear cell type, tumour fragments were never observed in the renal outflow. These 
data suggest that, in ccRCC, a VEGF-A-induced phenotype promotes a release of tumour cell 
clusters into the circulation that may contribute to pulmonary metastasis.
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Introduction
The mechanisms by which tumours disseminate are poorly understood. The ‘seed-and-soil’ 
hypothesis of Paget1 has been embraced as a plausible explanation for the organ preferences of 
different tumour types with respect to metastatic spread2,3. In this model, tumour cells (the ‘seeds’) 
escape from the primary tumour, spread throughout the body but grow out only successfully in 
a preferred target organ (the ‘soil’). Indeed, for some tumour types local reciprocal interactions 
between stroma and tumour cells have been described that allow clinically relevant outgrowth of 
metastases4. Examples are the paracrine interactions between prostate and mammary carcinoma 
cells with osteoblasts and osteoclasts, turning bone into a preferred metastatic niche for these 
cancer types5. Clinical experience suggests that such relations exist for other tumour types as 
well (e.g. melanoma metastasis in brain) but the underlying molecular and cellular mechanisms 
remain largely uncovered6.
The metastatic patterns of certain other tumour types suggest that alternative mechanisms of 
metastasis are operative as well. Colon carcinomas growing in the vicinity of the portal circulation 
generally give rise to hepatic metastases, whereas the more distally situated rectal cancers may 
disseminate towards the lungs. This suggests that after escape into the circulation, tumour cells 
are trapped in the first encountered capillary bed. Obviously, circulating tumour cell clusters, the 
presence of which had already been demonstrated in animal models over 30 years ago7, are 
predicted to be entrapped in a narrowing vasculature more efficiently than single tumour cells.
In a previous report we showed that constitutive over-expression of vascular endothelial growth 
factor-A (VEGF-A) in a mouse model of subcutaneous melanoma drastically increased metastatic 
burden to the lungs, and we identified circulating tumour cell clusters to be responsible for this 
behaviour8. These clusters consisted of small multicellular tumour nodules encapsulated by vessel 
wall elements. Based on these findings, we proposed a model in which, in primary tumours with 
constitutive VEGF-A expression, groups of tumour cells start to bulge out into VEGF-A-dilated 
vasculature, ultimately resulting in a collection of (partly) intravasated tumour nodules. This gives 
these tumours a so-called ‘micronodular’ appearance. Especially in the periphery of such tumours, 
the highly dilated vasculature facilitates escape of tumour cell clusters into the circulation, which 
is then followed by lung embolization. Interestingly, pulmonary metastases did not develop 
efficiently when the same VEGF-A-expressing tumour cells were injected intravenously. Instead, 
this primarily resulted in the development of brain metastases. These data suggest that melanoma 
cells may make their way into the brain only when they can pass the lung microvasculature and 
find access to the brain, ie as single cells.
Growth patterns characterized by the presence of multicellular clusters surrounded by vessel 
wall elements, similar to our angiogenic melanoma xenograft model, have been described for 
several tumour types, including renal cell carcinoma of the clear cell type (ccRCC)9, a prototype 
tumour with respect to its high constitutive VEGF-A expression10. ccRCC often disseminates to the 
lungs, although other tissues are also frequently involved. ccRCC is generally highly vascularized, 
a direct result of mutations in the Von Hippel–Lindau protein (pVHL) and up-regulation of, 
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among others, VEGF-A gene expression11-13. The striking similarities between our experimental 
angiogenic melanoma xenograft model and ccRCC regarding VEGF-A expression, tumour 
vascular morphology and metastatic behaviour prompted us to investigate whether formation 
and shedding of tumour tissue fragments into the circulation has a human counterpart in ccRCC 
patients.
Methods
Patients
All patients gave informed consent before entering this study. Fifty-one previously untreated 
patients, suspect for renal cell carcinoma (RCC) and scheduled for radical nephrectomy, were 
included between March 2006 and December 2008. Forty-six tumours were of the clear cell type 
and five tumours were diagnosed as renal cancers, other than clear cell carcinomas. As these 
tumours do not constitutively express VEGF-A and do not display the characteristic nodular ccRCC 
phenotype, these were included in this study as control tumours. The pathological diagnoses are 
summarized in Table 1.
Analysis of renal venous blood
Two methods were used to collect renal venous outflow after nephrectomy. Venous blood was 
collected in EDTA-containing flasks directly after surgery while gently massaging the kidney (n = 
24 for clear cell RCC, n = 2 for non-clear cell RCC). Four tumours, all of the clear cell type, had to be 
omitted from analysis because venous blood could not be collected due to extensive intravascular 
coagulation and obstruction of the renal vein. To collect venous outflow more effectively, we 
shifted to a perfusion protocol of nephrectomy specimens (n = 22 for clear cell RCC, n = 3 for 
non-clear cell RCC). A balloon catheter was placed in the renal artery and the kidney was perfused 
with a controlled flow of 0.9% NaCl, using a peristaltic pump (Watson Marlow, Rotterdam, The 
Netherlands). Perfusion was continued at a rate of 30 ml/min until the perfundate was clear. 
Typically, 500–750 ml perfundate was produced. Outflow was filtered through a 75 μm mesh 
nylon sieve. After washing the filter with 0.9% NaCl, the retentate was collected, concentrated 
by centrifugation (500 × g for 5 min) and processed to paraffin-embedded AgarCyto-blocks14. 
After this procedure, primary tumour tissue was processed for standard diagnosis and 
immunohistochemical staining.
Immunohistochemistry
Agar cytoblocks and corresponding primary tumours were analysed by haematoxylin and 
eosin (H&E) staining and immunohistochemistry, using antibodies against CD34 (MEC14.7, 
Hycult Biotechnology bv, Uden, The Netherlands) or CD31 (Dako, Glostrup, Denmark) to detect 
endothelial cells, laminin (DakoCytomation, Denmark) to detect vessel basement membrane 
and α-smooth muscle actin (α-SMA; Sigma, Zwijndrecht, The Netherlands) to detect pericytes. 
Antibody M75 against the ccRCC tumour cell marker carbonic anhydrase-IX was provided by 
Dr E. Oosterwijk. In some cases the organization of tumour cells and endothelial cells in the 
tissue was visualized by double immunostaining for CA-IX and CD31, using Fast Red and Fast 
Blue for detection, respectively. Immunostaining for VEGF-A was performed with a mouse 
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monoclonal antibody (BD Pharmingen, Breda, The Netherlands). Proliferating tumour cells were 
detected using an antibody against Ki67. Antibodies were visualized by biotin-labelled secondary 
antibodies and avidin peroxidase, as previously described12. Primary tumours were assessed for 
VEGF expression, vessel density, micronodular phenotype and extent of microvascular invasion. 
Scoring for micronodular phenotype, based on CD31 stainings, was performed independently 
by two investigators (GK-U and WL). Heterogeneous tumours were also designated micronodular 
if this phenotype was present only focally, based on the underlying hypothesis that such focal 
spots may already suffice for the shedding of metastatic tissue.
Statistical analysis
As interim analysis already showed correlations between the presence of tumour cell clusters 
in venous outflow and pulmonary metastasis in both massage and perfusion groups, we 
considered it justified to pool the data from these groups. Relationships between micronodular 
phenotype, occurrence of tumour material in the renal outflow and the presence of pulmonary 
metastases were analysed in 2 × 2 contingency tables, using Fisher’s exact test (two-sided) in 
SPSS for Windows.
VEGF-A PCR
VEGF-A RNA levels were assessed by RT–PCR, as described12. Tumour mRNA samples (3 μg, 
isolated from frozen tumour sections) were treated with DNAse (Life Technologies, Breda, The 
Netherlands), reverse-transcribed (40 °C for 1 h; SuperScriptTM RT, Life Technologies) and subjected 
to standard PCR amplification, using Super Taq (HT Biotechnology Ltd) and VEGF-A-primers 
5’-GCACCCATGGCAGAAGGAGGA-3’ (sense) and 5’-TCACCGCCTCGGCTTGTCAC-3’ (anti-sense) 
for 30 cycles. This primer set amplifies all VEGF-A isoforms except VEGF165b15. Expected product 
lengths with this primer set are 367 bp (VEGF-121), 436 bp (VEGF-145), 496 bp (VEGF-165) 
and 568bp (VEGF-189). The housekeeping gene glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) was used as a control.
Results
Occurrence of tumour fragments in venous outflow correlates with tumour morphology
Patient and tumour characteristics are depicted in Table 1. Five tumours in our group were in 
retrospect not of the clear cell type (Table 1). Because of a lack of constitutive VEGF expression 
and micronodular phenotype (not shown), we used these tumours as negative controls. We 
did not detect tumour clusters in renal venous outflow samples of these patients. Two of these 
patients (one with papillary carcinoma and one with collecting duct carcinoma, 9.8 and 18 cm 
diameter, respectively) presented with lung metastases.
In the 42 clear cell carcinomas that were amenable for analysis, tumour clusters were detected 
in venous outflow in 14 cases (33%; Tables 1,2). Twelve of these were classified as T3b tumours 
according to the TNM Atlas16; the remaining two were T3a. The diameters of the corresponding 
primary tumours were significantly larger than those without tumour clusters [11.1 ± 2.8 (range 
6.0–16.5) cm versus 7.8 ± 4.2 (range 2.2–22) cm], mean diameter ± SD, p = 0.015, two-tailed 
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t-test). Twelve of the 14 cases that produced tumour clusters (86%) had lung metastases at the 
time of surgery or dormant metastases that became symptomatic later on. Conversely, of the 28 
remaining patients in whom no clusters were found, 21 (75%) did not develop lung metastases 
(with a follow-up of at least 1 year after tumour nephrectomy). In this group, diagnoses ranged 
from T1a or T1b (n = 7) to T2 (n = 5), T3a or T3b (n = 15) and T4 (n = 1). There were no obvious 
differences between the groups with or without metastases with respect to tumour staging. As 
can be expected from a clinico pathological view, T1 tumours all fell in the group of unmetastasized 
tumours without tumour emboli.
A significant correlation between tumour fragments in venous outflow and pulmonary metastases 
was found (p< 0.001, Table 2A). Also, a micronodular phenotype of the primary tumour correlated 
significantly with the presence of shed tumour fragments (p= 0.003, Table IIB).
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Figure 1. Morphology of metastasizing ccRCC. Shown are H&E staining (a) and CD31 endothelial staining (b) of a 
ccRCC at the border of the tumour. Note the numerous apparently free-lying tumour nodules, covered with CD31-
positive endothelial cells, within the vasculature. (c) VEGF-A is abundantly expressed by this tumour. (d–f) H&E 
(d), MIB1 (e) and CD31 (f) staining of ccRCC, but distant from the main tumour mass. Intravascular groups of 
proliferating tumour cells in the surrounding tissue can be observed [arrows in (d) and (e); arrowheads in (e) point 
to erythrocytes]. Original magnification, × 50
Figure 2 shows characteristic examples of tumour fragments that were isolated from venous 
outflow samples. Endothelial cells, identified by CD34 and/or CD31 staining, and pericytes 
(positive for αSMA) were associated with tumour fragments in 29% of cases (4/14) and coverage 
was either partial (Figure 2a–e) or complete (Figure 2f–g). The number of tumour clusters that 
could be found in AgarCyto blocks varied considerably, sometimes being only one. Numerical 
analysis was not performed as the experimental procedure is amenable to high variations in 
detection.
3. Tumour fragments as the source of metastasis
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Figure 2. Tumour cell clusters in renal vein outflow. Three cases are presented: (a) immunostaining for tumour 
cell marker CA-IX; (b, d, f) CD34 or CD31 staining for endothelial cells, as indicated; (c, e, g) laminin staining for 
basement membrane. Note that association with endothelial cells is infrequent. Original magnification, × 200
As expected, all ccRCC tumours expressed high levels of predominantly VEGF-A121 and VEGF-A165, 
although the 145 and 189 isoforms were also frequently detected (Figure 3)12. In general, VEGF-A 
expression was higher in ccRCC than in renal cancers that were not of the clear cell type. PCR data 
were confirmed by immunohistochemistry for VEGF-A, showing high and constitutive VEGF-A 
expression in most ccRCCs (see Figure1c), although expression was heterogeneous within this 
group. The VEGF-165b variant15,17 was not detected in our samples (not shown).
Figure 3. VEGF-expression in ccRCC. Note that VEGF-A121 and VEGF-A165 are prominently expressed in all ccRCC 
cases and lower expression in non-ccRCC tumours. Lanes 1–3, representative examples of ccRCC; lane 4, papillary 
carcinoma; lane 5, angiomyolipoma; lane 6, oncocytoma; lane 7, urothelial carcinoma
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Discussion
During the initial steps of metastasis, tumour cells have to gain access to the circulation to 
be carried to distant sites. According to the generally accepted concept, metastasis involves 
protease-mediated active migration through extracellular matrix, followed by disruption of the 
vessel basement membrane18,19, thereby identifying matrix protease inhibitors as a treatment 
option20,21. We and others have previously demonstrated the existence of an alternative and 
protease-independent mechanism of metastasis8,22. According to this concept, constitutive 
and high VEGF-A expression warrants the presence of dilated vessels, especially in the tumour 
periphery, where these vessels are not compressed, into which expanding tumour nests can 
bulge out. This bulging process is accompanied by a gradual coverage of tumour clusters by 
vessel wall elements, which is accommodated by proliferating endothelium and other mural 
cells. As this process proceeds, tumour tissue emboli enveloped by blood vessel wall elements 
can become detached, enter the circulation and become trapped in narrowing vessels, followed 
initially by intravascular outgrowth8,22. The characteristic micronodular phenotype of the primary 
tumour that is associated with this phenomenon can be induced in experimental melanoma by 
constitutive over-expression of VEGF-A8 and has been observed in a range of human tumours, 
including renal cell carcinoma9.
In this study we show that this process may be clinically relevant, as 86% of patients from whom 
tumour cell clusters could be isolated carried or developed lung metastases, whereas 25% of 
ccRCC patients without tumour clusters presented with lung lesions (p < 0.001). In the latter 
group, 72% of primary tumours had a micronodular phenotype and may have shed tumour 
clusters that were missed in our analysis. Alternatively, a role for smaller groups of tumour cells or 
even single cells that were not retained on our 75 μm filter can obviously not be excluded in this 
group. Still, the correlation between tumour phenotype, the presence of shed tumour fragments 
and pulmonary metastases is in line with the hypothesis that intravascularly localized cell clusters 
in dilated tumour vasculature, rather than single cells, escape into the circulation and are the 
primary source of the pulmonary metastases.
In the ccRCC group, the presence of shed tumour fragments and the occurrence of metastases 
were both significantly correlated with tumour size. This may be simply explained by an increased 
chance of tumour emboli shedding, due to the larger tumour volume. A correlation between 
tumour size and poor prognosis for renal cancer has been observed previously, and the cut-off 
value to discriminate between T-I and T-II tumours according to TNM criteria is 7 cm23,24, which is 
below the average tumour size in both groups, ie with and without tumour clusters. We therefore 
conclude that shedding of intravascular tumour fragments is a clinically relevant phenomenon 
that may occur more frequently in large tumours with a micronodular phenotype.
Constitutive VEGF-A expression appears to be a prerequisite but probably does not suffice to 
induce release of tumour cell clusters. Possibly, the actual release is a stochastic process that 
depends on local factors, such as the presence of non-compressed and dilated vasculature at 
the tumour rims. Conversely, metastasis via VEGF-A-induced tumour embolization can not be 
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the only metastatic pathway, as non-ccRCC tumours without a micronodular phenotype also 
develop lung metastasis. Also, even in ccRCC tumours with a micronodular phenotype, (groups 
of ) tumour cells can often be observed invading the surrounding tissue without obvious contact 
with blood vessels. Whether these invading tumour cells also contribute to the development of 
metastases is difficult to ascertain. These cells may give rise to metastasis via the classical pathway, 
traverse the lung capillaries and re-enter the circulation via the pulmonary veins. Subsequently, 
they are captured in organs such as bone and brain, other common sites that are fertile soil for 
ccRCC metastases.
There are a number of arguments that favour this hypothesis. First, the distribution of metastases 
strongly depends on the route of administration in mouse models: in one study, intravenous 
injection of mammary carcinoma cells in nude mice resulted in abundant lung metastases 
and hardly any bone lesions, while intracardiac injection resulted in the reverse phenotype25. 
Second, the composition of metastases depends on the amount of cells injected: intravenous 
injection of high numbers of tumour cells generated polyclonal pulmonary lesions, whereas 
low numbers of tumour cells generated monoclonal pulmonary metastases26, possibly because, 
when using high numbers of cells, tumour cell aggregates are formed that are trapped upon 
intravenous injection. Third, we previously found that intravenous injection of small numbers of 
melanoma cells resulted in a low tumour burden in the lungs, whereas abundant predominantly 
monoclonal brain metastases were present in the same animals. Tumours grown from the same 
cells efficiently metastasized to the lungs out of a subcutaneous location8. Additionally, when a 
highly concentrated suspension of the same tumour cells was injected intravenously, polyclonal 
lung lesions developed, which could be attributed to trapping of multicellular aggregates that 
were formed in the dense tumour cell suspension (unpublished results).
According to the ‘seed and soil’ hypothesis, tumour cells need to find fertile ‘soil’ for sustained 
outgrowth, and this is highly dependent on specific interactions between tumour cells and 
environmental cues. This situation may be different when tumours metastasize as emboli, since 
intimate contacts between tumour cells and/or vessel wall elements in the emboli we describe 
here may prevent anoikis (detachment-induced apoptosis)27. Therefore, the tissue character 
of metastatic tumour emboli may provide a self-sustaining environment that allows tumour 
outgrowth. We previously hypothesized that endothelial coverage of tumour clusters may hide 
tumour cells from the immune system and protect against shear forces in the circulation and 
platelet aggregation8. Our current study suggests that coverage with vessel wall elements is of 
minor importance. How tumour fragments can escape from the tumour without taking along 
vessel wall elements is not clear. Tumour growth per continuum in the vena renalis is frequently 
observed in ccRCC and mechanical disruption of these intravascular tumour structures may 
certainly contribute to metastasis28.
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We previously showed that the metastatic phenotype of angiogenic melanoma xenografts was 
effectively inhibited using the VEGFR2 tyrosine kinase inhibitor vandetanib (ZD6474)8. Recent 
results from our laboratory have revealed that escape of tumour emboli from the tumour is a 
relatively early event in this model, occurring during the first 2 weeks after tumour cell inoculation 
(manuscript in preparation). If these findings were to be translated to clinical ccRCC, it would 
be a good argument to start with anti-VEGF therapy in a neo-adjuvant setting directly after first 
diagnosis. Phase II studies with neo-adjuvant sunitinib (a tyrosine kinase inhibitor, specifically 
targeting the VEGF and PDGF receptors) for ccRCC are currently ongoing in our hospital. It would 
be highly interesting to investigate the effects of these compounds on shedding of tumour 
emboli into the circulation. We are currently pursuing this issue.
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Abstract
Backgound 
Clear cell renal cell carcinoma (ccRCC) is characterized by high constitutive vascular endothelial 
growth factor-A (VEGF-A) production that induces a characteristic vascular phenotype. We 
previously reported that this phenotype may allow shedding of multicellular tumor fragments 
into the circulation, possibly contributing to the development of metastasis. Disruption of this 
phenotype through inhibition of VEGF signaling may therefore result in reduced shedding of 
tumor fragments and improved prognosis. To test this hypothesis, we investigated the effect of 
sorafenib treatment on tumor cluster shedding.
Patients and Methods 
Patients with renal cancer (n=10, of which 8 have ccRCC) received sorafenib for 4 weeks before 
tumor nephrectomy. The resection specimens were perfused and the perfundate was examined 
for the presence of tumor clusters. Effects of the treatment on the tumor morphology and overall 
survival were investigated (follow-up of 2 years) and compared with a carefully matched control 
group.
Results
Neoadjuvant sorafenib treatment induced extensive ischemic tumor necrosis and, as expected, 
destroyed the characteristic ccRCC vascular phenotype. In contrast to the expectation, vital 
groups of tumor cells with high proliferation indices were detected in post-surgical renal venous 
outflow in 75% of the cases. Overall survival of patients receiving neoadjuvant treatment was 
reduced compared to a control group, matched with regard to prognostic parameters.
Conclusions
These results suggest that neoadjuvant sorafenib therapy for ccRCC does not prevent shedding of 
tumor fragments. Although this is a nonrandomized study with a small patient group, our results 
suggest that neoadjuvant treatment may worsen survival via as yet undefined mechanisms.
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Introduction
Although the molecular and cellular mechanisms that are involved in metastatic spread of tumors 
are gradually being unravelled, much is still poorly understood. Because metastatic disease is the 
leading cause of death of patients with cancer, deciphering these mechanisms is of extreme 
importance. The currently most popular paradigm is the seed and soil hypothesis, put forward 
by Paget already in 18891. This hypothesis states that solitary tumor cells that are shed from a 
tumor (the seeds) can develop into clinically relevant lesions only in compatible tissues (the soil) 
where interactions with the specific tissue micro-environment allow tumor outgrowth. Epithelial-
to-mesenchymal transition (EMT) is nowadays seen as a key developmental program that needs 
to be activated during cancer invasion and metastasis2. The mesenchymal phenotype allows cells 
to migrate and spread through surrounding extracellular matrix in a protease-dependent manner 
before eventually invading into blood vessels and entering the circulation3,4.
We and others have proposed an alternative mechanism of metastasis that is independent 
of EMT and does not require proteolytic degradation of the vessel wall5-7. When investigating 
effects of constitutive overexpression of Vascular Endothelial Growth Factor A (VEGF-A) on tumor 
histology and biology, we found that this factor induced a highly metastatic phenotype in 
melanoma xenografts. This phenotype could be attributed to VEGF-A–induced development of 
a so-called micronodular phenotype, which develops by budding of clusters of tumor cells into 
dilated tumor vasculature. During this budding process the clusters become gradually covered 
with vessel wall elements as they enter the blood vessel. We demonstrated that these clusters 
may eventually enter the circulation and are ultimately caught in the lung vasculature where they 
may grow out to pulmonary metastases5.
In approximately 80% of clear cell Renal Cell Carcinomas (ccRCC) the Von Hippel- Lindau (VHL) 
gene is mutated resulting in non-functional Von Hippel Lindau protein (pVHL)8. As normal pVHL 
is involved in the controlled degradation of hypoxia- inducible factor 1 α, pVHL mutations result 
in accumulation of this transcription factor and constitutive expression of its target gene VEGF-A, 
also under normoxic conditions9. The majority of VEGF-A- expressing ccRCCs present with 
a micronodular phenotype10. We previously reported that ccRCC tumor cell clusters are often 
located in the lumen of vessels and enter the circulation11. We observed a correlation between the 
occurrence of these clusters in renal venous outflow and the presence of pulmonary metastases 
suggesting that shedding of tumor cell clusters into the circulation results in subsequent capture 
in the lung capillary bed, followed by outgrowth.
The well-recognized importance of VEGF and PDGF signaling pathways in ccRCC has provided 
a rationale for treating patients with metastatic and progressive disease with tyrosine kinase 
inhibitors, among which is sorafenib, a small molecule inhibitor of VEGF receptor and platelet 
derived growth factor receptor tyrosine kinases and RAF kinase12-14. Although these therapies are 
indicated for disseminated disease, patients with locally extensive RCC have also been treated 
in phase II trials in a neoadjuvant setting with the aim to reduce tumor size and downstage 
the tumors, facilitating complete resection15-17. Limited histopathologic data show extensive 
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necrosis and fibrosis in the primary tumor on neoadjuvant treatment, although a risk of 
fulminant angiogenic outgrowth during drug-holidays has been observed18. The destruction of 
the micronodular phenotype of the tumor, which is a direct result of anti-VEGF treatment, may 
also impinge on the metastatic potential of these tumors, as has been suggested in previous 
preclinical studies5.
Here, we investigated the effects of neo-adjuvant sorafenib treatment on the histopathology of 
the primary tumor, on shedding of tumor cell clusters into the circulation, and on survival.
Materials and Methods
Patients
The study described here was a side study to Trial nr. NCT08602862 in which molecular imaging 
is performed on patients with renal cell cancer after neoadjuvant sorafenib treatment. Part of 
the data from the trial have been published before19,20. All patients included in this study signed 
informed consent. Ten patients were included in a period of 2 years. Eligible for sorafenib treatment, 
followed by nephrectomy, were patients with RCC with a Karnoffsky score >70% who did not 
receive prior chemotherapy, immunotherapy or radiation therapy. The decision to participate in 
the study was not further influenced by clinical performance as Motzer scores were calculated 
only at poststudy evaluation. Patient characteristics and clinicopathologic parameters have been 
published before, and an updated summary is given in Table I, with more detailed information on 
individual cases in supplementary Table 219. TNM staging was performed according to the TNM 
classification, seventh edition. Tumors were classified as ccRCC (n=8), chromophobe RCC (n=1) 
and papillary RCC (n=1). All tumors were pT3a, pT3b or pT4 and G2 to G4. Seven patients in the 
treatment group were in retrospect suspect for having metastatic disease. Patients were treated 
for 4 weeks with sorafenib (400 mg twice a day), and nephrectomy was performed 3 days after 
the last administration.
For survival analyses, we carefully composed a control group of 12 patients with ccRCC patients 
from our previous study who underwent tumor nephrectomy without any neoadjuvant 
treatment11. This group was matched to the treatment group with respect to TNM staging. All 
patients in this control group had also confirmed metastatic disease at first presentation.
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Perfusion of nephrectomy specimen and analysis of renal venous blood
Renal outflow from tumor nephrectomies was examined essentially as described11. In short, a 
balloon catheter was placed in the renal artery, and the kidney was perfused with a controlled 
flow of 0.9% NaCl using a peristaltic pump (Watson-Marlow, Rotterdam, The Netherlands). 
Perfusion was continued at a rate of 30 ml/min until the perfundate was clear. Typically, 500- 
750 ml perfundate was collected. Outflow was filtered through a 75-μm mesh nylon sieve. After 
washing the filter with 0·9% NaCl, the residue was collected, concentrated by centrifugation (500g 
for 5 min), and fixed in Unifix (Klinipath, Duiven, The Netherlands). Subsequently AgarCyto-blocks 
were prepared by carefully resuspending the fixed residue in 2% liquid agarose (LE, analytical 
grade, Promega, Madison WI) followed by standard paraffin embedding of the solidified agarose 
blocks21. After this procedure, primary tumor tissue was processed for standard diagnosis and 
immunohistochemical staining.
Immunohistochemistry
AgarCyto blocks and corresponding primary tumors were analysed by haematoxylin and eosin 
(H&E) staining and immunohistochemistry using antibodies against CD31 (Dako, Glostrup, 
Denmark) to detect endothelial cells, collagen IV (Abcam, Cambridge, UK) to detect vessel 
basement membrane, α-smooth muscle actin (Sigma, Zwijndrecht, The Netherlands) to detect 
pericytes and carbonic anhydrase-IX (M75, Dr. Oosterwijk) to detect tumor cells22. Proliferating 
tumor cells were detected using an antibody against Ki67 (clone sp6, Abcam). Inflammatory cells 
were detected using antibodies against CD2 (Neomarkers, Fremont, CA) to detect T-lymphocytes 
and myeloperoxidase (MPO, Neomarkers) to detect granulocytes. Antibodies were visualized by 
appropriate biotin-labelled secondary antibodies and avidin peroxidase (Vector Laboratories, 
Burlingame, CA), as previously described23. Primary tumors were assessed for necrosis, blood 
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vessel wall changes, carbonic anhydrase-IX expression, micronodular phenotype, (micro)vascular 
invasion and inflammation. To minimize sampling errors, at least 10 paraffin blocks taken from 
different areas from each tumor were analyzed. Ten untreated ccRCCs from our local pathology 
archive were included as controls to assess extent of necrosis. Scoring for micronodular phenotype, 
based on CD31 stainings, was performed independently by two investigators (G.K.-U. and W.L.). To 
quantify inflammatory cells, MPO and CD2 immunoreactivity was scored independently by two 
pathologists (H.v.K and G.K.-U.) as ranging from 0 (no stained cells) to 3 (high density of positive 
cells). In case of discordance consensus was reached at a double-headed microscope.
Statistical analysis
Relationships between neoadjuvant treatment and occurrence of tumor material in renal outflow 
were analyzed in 2 x 2 contingency tables using Fisher’s exact test (two-sided) in IBM SPSS 
Statistics version 20.0 (Chicago, IL). Median survival differences were tested in GraphPad Prism 
version 5.03 (Graphpad Software Inc., San Diego, CA) for significance using a Mantel-Cox test and 
were considered significant at p<0.05.
Results
Effects of sorafenib treatment on primary tumors
We first analyzed the effects of neo-adjuvant sorafenib treatment on the histopathology of 
RCCs. In our series, two renal tumors were of the nonclear cell type. These tumor types do not 
constitutively express VEGF-A and do not present with a micronodular vascular phenotype. We 
included these tumors also in the analyses to investigate if lack of constitutive VEGF expression 
affects response to sorafenib. Effects of sorafenib on the morphology of these tumors were 
minimal (not shown). In contrast, sorafenib induced profound effects on the ccRCCs; these all 
showed extensive areas of necrosis, although areas of vital tumor tissue were still present (Figure 
1, A and B). At macroscopic cross-sectioning, abundant liquefactive necrosis was observed more 
often than in historical control tumors that had been processed similarly in our department (not 
shown).
Histologically, the treated ccRCCs frequently showed prominent edema and fibrinoid necrosis 
of the blood vessel walls (Figure 1, C and D, arrows). Vessel lining by endothelial cells was often 
discontinuous, with fragmentation and sometimes thrombus formation (Figure 1E, arrow). In 
central necrotic areas, remnants of necrotic vessels were also observed (Figure 1A). Importantly, 
the vascular changes induced by sorafenib were tumor specific as vessels in normal renal tissue 
distant from the tumor showed a normal appearance (not shown). Furthermore, the vasculature 
in vital tissue in control (nontreated) ccRCC showed a regular endothelial lining (Figure 1F).
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Figure 1. Histological analysis of effects of sorafenib treatment on primary tumor. Throughout the tumor, extensive 
areas of necrosis are seen (H&E staining in panel A, note also necrotic remnants of blood vessels) whereas also areas 
of vital tumor can be observed, interspersed with heavily inflamed fibrovascular structures (see H&E staining in B). 
A spectrum of tumoral blood vessel responses to sorafenib treatment is seen, ranging from edema of the vessel 
wall (see arrows in C) to fibrinoid necrosis with endothelial cell fragmentation, fibrin deposition and inflammatory 
cells (D, arrow) and obliteration (E, arrow). For comparison, panel F shows a non-treated control tumor with the 
characteristic micronodular phenotype and undamaged blood vessels (arrow). Magnifications A 25x; B,C 50x; D-F 
100x.
In seven of eight ccRCCs, prominent blood vessel (micro) invasion was observed (Table I). None of 
the treated tumors showed a micronodular phenotype (not shown) whereas this phenotype was 
seen in 45% of the non-treated tumors11.
In treated tumors intratumoral lymphocyte densities were higher than in control tumors (78% 
score 2 or higher vs 50% in control tumors, Figure 2 and Table 3). A consistent observation was 
that very high densities of lymphocytes were found associated with fibrovascular structures 
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(Figure 1B, arrows, and 2, A and B) and damaged tumor vasculature (Figure 2, C and D) whereas 
nontreated ccRCC showed some lymphocytic infiltrates mainly concentrated in the tumor rim 
(Figure 2, E en F). Granulocyte counts as determined by MPO staining were in general low (not 
shown).
Figure 2. Inflammatory response in renal cell carcinoma after neo-adjuvant sorafenib treatment. Shown are serial 
sections, stained with H&E (A) and the T-lymphocyte marker CD2 (B). Note heavy infiltration of CD2 positive cells 
in panel B and perivascular lymphocytes in C and D (arrow). Panels E and F show H&E staining and CD2 staining 
respectively of serial sections of an untreated tumor (E). Lymphocyte infiltration is much less profound and is 
mainly localized in the rim of the tumor (arrow in F).
TREATED
UNTREATED
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Presence of tumor cell groups in the perfundate
In six of eight patients with ccRCC in the neo-adjuvant group (75%), small groups of CA-IX- positive 
tumor cells (3-15 cells) could be detected in the filtered perfundate (a representative example is 
shown in Figure 3A; see also table III). The cells were sometimes loosely attached to each other 
and showed irregular cytoplasmic extensions. All these groups contained proliferating tumor 
cells (Ki67 staining in Figure 3B). Association with endothelial cells or pericytes, as demonstrated 
by CD31 or α-SMA staining, was not observed in any of the collected tumor cell groups (not 
shown). This was in contrast to our previous study, where we found vessel basement membranes 
and/or endothelial cell linings in 30% of tumor cell clusters in untreated patients (see example in 
Figure 3C)11. Venous outflow material from the chromophobe and papillary RCC did not contain 
tumor cells or clusters (Table I).
Figure 3. Characteristic example of a tumor cell group, collected after perfusion of a clear cell renal cell carcinoma 
nephrectomy specimen. Tumor origin of the cells is evidenced by immunohistochemical staining for the ccRCC 
marker CA-IX (A). Note the high proliferation index in this tumor cell cluster as evidenced by immunostaining for 
the proliferation marker Ki-67 (B). Magnification: 400x. C shows an example of a laminin-stained tumor cell cluster 
from the control group illustrating that this cluster is covered by wall elements. Scale bar, 50μm.
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Effect of neo-adjuvant sorafenib treatment on survival
Because the control group was heterogeneous and to prevent bias, the control group was narrowed 
down to match the treated group with respect to disease stage and pathophysiological and 
clinical parameters, ultimately resulting in 12 control patients and 7 patients in the neoadjuvant 
group (see Table 2). Kaplan- Meier analysis of patients in the neo- adjuvant group revealed 
significantly poorer overall survival than the control group (Figure 4)11. Even with this small group, 
a significantly longer median survival was found in the control group (66 months, range = 13-85 
months, six patients still alive), compared to the patients in the neoadjuvant sorafenib treated 
group (10 months, range = 7-71 months, one patient still alive); P=.038. This resulted in a hazard 
ratio of 4.42 (confidence interval = 1.09 - 16.81).
Figure 4. Kaplan Meyer survival curve showing a significant decrease in overall survival in the neo-adjuvant 
treatment group.
Discussion
We previously reported that in 33% of patients with ccRCC tumor cell clusters can be detected in 
renal venous outflow and that the occurrence of these shed clusters correlates with the presence 
or metachronous development of pulmonary metastasis11. The presence of such tumor tissue 
fragments was also associated with the micronodular phenotype that is characteristically found 
in tumors with high VEGF-A expression6,10. Disruption of the VEGF-A-induced micronodular 
phenotype by VEGFR2 inhibition in a mouse model of human melanoma xenografts effectively 
inhibited pulmonary metastasis5. In the present study, the effects of blocking VEGF-A activity with 
sorafenib on shedding of tumor cell clusters from human renal cell cancers was investigated.
Sorafenib treatment of papillary and chromophobic RCC (lacking constitutive VEGF expression) 
was apparently ineffective: these tumors contained minimal amounts of necrosis and hypoxia and 
contained high vessel densities (data not shown). In contrast, treatment of the ccRCCs destroyed 
the characteristic micronodular phenotype and induced extensive necrosis, although large vital 
areas were still present in all tumors. These areas homogeneously expressed CA-IX20, confirming 
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the clear cell origin of these tumors. The vascular endothelium in treated ccRCCs was damaged, 
resulting in edema of the vessel walls, vasculitis, and fibrinoid necrosis. Although on the basis 
of its tyrosine kinase inhibition profile, sorafenib affects endothelial cells, we cannot completely 
exclude additional direct proapoptotic effects on tumor cells, as has been suggested before24.
In contrast to the initial expectation of lower shedding of tumor cell groups, these were still 
observed in 75% of sorafenib-treated patients. This was in line with the notion that seven of 
eight patients had in retrospect suspected metastatic disease at the start of treatment. In the 
subgroup of metastasized patients in the control group, a similar percentage was seen (66%). We 
therefore conclude that neoadjuvant sorafenib treatment does not have impact on the shedding 
of tumor clusters. Of importance, most of the tumor cell groups in the treatment group contained 
viable and even proliferating cells. These cell groups were deprived of an endothelial cell lining, 
in contrast to those in control patients where 30% of clusters were associated with vessel wall 
elements.
The mechanism of tumor cluster shedding from treated nonmicronodular tumors is not clear. All 
patients in whom tumor cell groups were detected in the perfundate of the postnephrectomy 
venous outflow presented with (micro)vascular invasion of tumor in the vital tumor areas. Shed 
tumor cell groups may therefore represent the vital remnants of these intravascularly located 
tumor fragments that are shed from a destroyed tumor vasculature. Sorafenib-induced destruction 
of the tumor vasculature and damaged vessel walls may also facilitate direct entry of the tumor 
cell clusters into the circulation. Absence of vessel wall elements suggests that entrance of these 
cell clusters into the circulation occurs through a mechanism that is distinct from intravascular 
budding. Alternatively, the micronodular phenotype, which had been initially present, may have 
been destroyed by sorafenib by a direct toxic effect on endothelial cells, resulting in denudation 
of the endothelial covering of the intravascular buds. Of interest, a short course of antiangiogenic 
tyrosine kinases has been shown to provoke a more invasive tumor phenotype in animal models 
of cancer25,26. It remains to be established whether our observations have a physiological link to 
these data.
We have previously examined the effects of anti-VEGF therapies on angiogenic melanoma 
xenografts in mice and found a reduction in the number of metastases in the lungs. This may 
be explained by the fact that in that situation, the formation of a micronodular phenotype is 
prevented, whereas in the current clinical study, established tumors with such phenotype are 
subjected to treatment.
Our study suggests that neoadjuvant sorafenib treatment has a negative impact on prognosis. 
However, we realize that there are limitations to our study. As this was a side study to clinical trial, 
designed to assess the effect of sorafenib on antibody-mediated molecular imaging, the setup did 
not allow a randomized approach, and clinicopathologic parameters could only be determined 
postnephrectomy. Furthermore, the number of included patients was limited, and importantly, 
retrospective analysis revealed that most of the patients in the treatment group had metastatic 
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disease already at the start of the treatment. It would be of high importance to study the effects 
of neoadjuvant treatment in patients without evidence of metastatic disease. In addition, there 
were differences in treatment regime at tumor recurrence that may have impacted on survival 
(see Tabel 2). On the basis of our data, it is not possible to judge the potential predictive value 
of Motzer scores for response to neoadjuvant treatment. Yet, the highly significant negative 
effect of neoadjuvant treatment on survival (hazard ratio = 4.4) in this small patient population 
indicates that the use of sorafenib for neoadjuvant treatment of ccRCCs, especially in patients 
with metastatic disease, should be reconsidered and further studies are needed on the basis of 
the ongoing trials. Whether this study should be extended to larger groups of patients should 
be a serious matter of debate given our results25,26. Of note, treatment with sunitinib, a tyrosine 
kinase inhibitor with a similar target specificity as sorafenib, in a phase II neoadjuvant setting did 
not reveal a negative effect16. Whether this is related to intrinsic differences between sorafenib 
and sunitinib is unclear.
Another intrinsic limitation of our study is that the study design did not allow pretreatment 
tumor sampling. However, because more than 80% of ccRCCs show VHL mutations leading 
to high VEGF-A levels and a micronodular phenotype, we consider it justified to assume that 
the absence of this phenotype in the tumors in the present study is the result of the sorafenib 
treatment. A final potential drawback is that sorafenib treatment was stoppped 3 days before 
tumor nephrectomy during which theoretically morphologic changes may occur. This 3-day 
period is inevitable to prevent wound-healing complications. It was recently described that 
discontinuation of sunitinib treatment in patients with ccRCC in a neoadjuvant setting may result 
in compensatory angiogenesis and a tumor rebound effect27. In the sorafenib-treated tumors of 
the current study, no indication for this phenomenon was found, but the time span between the 
end of the study and subsequent surgery might have been too short. Neoadjuvant treatment 
of patients with ccRCC with the anti-VEGF antibody bevacizumab does not appear to cause 
compensatory angiogenesis, possibly due to its circulation half-life of approximately 21 days27. 
Although it would be interesting to investigate the effects of this anti-VEGF antibody on tumor-
cluster shedding, such studies are not feasible because of expected wound healing complications 
during the nephrectomy.
A remarkable observation was the profound inflammatory response in the vital tumor areas that 
was significantly higher than in control tumors. How this inflammatory response contributes 
to tumor biology is unclear. Sorafenib has been shown to inhibit natural killer cell- mediated 
cytotoxicity in vitro, an effect that was not seen with sunitinib28. Conversely, it has been shown that 
sorafenib decreases the influx of immune-suppressing regulatory T cells (Treg) in clinical samples 
of ccRCC, potentially leading to an enhanced immune response and clinical outcome19. If and 
how the counteractive effects have contributed to reduced survival in the group of sorafenib-
treated patients are not clear, and a more detailed analysis of the lymphocytic infiltrates in treated 
versus control tumors will be needed to evaluate the effects of these therapies on antitumor 
immunity.
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In conclusion, this study strongly suggests that neoadjuvant sorafenib treatment of ccRCC 
destroys the characteristic VEGF-A-induced micronodular phenotype of these tumors, causes 
specific changes in tumor vasculature, and induces profound necrosis as wel as intratumoral 
inflammation. In contrast to the initial expectations, neoadjuvant treatment did not reduce 
shedding of tumor fragments into the circulation. Furthermore, neoadjuvant sorafenib treatment 
of metastasized patients with ccRCC may worsen prognosis.
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Better e ect of sorafenib on the 
rhabdoid component of a clear cell 
renal cell carcinoma owing to its 
higher level of vascular endothelial 
growth factor-A production
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5. Correspondence
Antiangiogenic treatment of clear cell renal cell carcinoma (ccRCC) targeting different steps of 
the tyrosine kinase (TK) cascade has brought a revolutionary change in the management of 
metastatic disease. These agents affect the blood flow around or to a tumour by blocking the 
effects of vascular endothelial growth factor (VEGF)-A in the TK cascade. The small-molecule 
TK inhibitors sorafenib and sunitinib target VEGF receptor 2 and platelet-derived growth factor 
receptor and prevent downstream signalling1. These agents are also used in experimental settings 
in adjuvant and neo-adjuvant therapy regimens to increase progression-free disease survival or 
downsize tumours in patients with locally extensive or metastatic ccRCC2,3.
ccRCC is the most common malignancy of the kidney. ccRCC with rhabdoid features is an 
aggressive variant of ccRCC, and accounts for approximately 5% of adult RCC cases. The rhabdoid 
component is defined on the basis of morphological features, and its presence is related to high 
histological Fuhrman grade and advanced pathological stage4. The rhabdoid and non-rhabdoid 
components in composite tumours have been shown to carry the same genetic aberrations, 
suggesting that these histologically distinct patterns arise from the same malignant precursor 
cell5.
Here, we present a patient in whom histological changes in a primary ccRCC with rhabdoid 
features after 1 week of neo-adjuvant treatment with sorafenib were observed. The rhabdoid 
component of the tumour was more sensitive to sorafenib treatment.
A 59-year-old woman with rheumatoid arthritis, hypertension and depression was diagnosed 
with a mass suspicious for ccRCC in the upper pole of the left kidney. Clinical staging studies 
showed no metastases. The patient was referred to our university hospital for laparoscopic 
nephrectomy. At admission, she was enrolled in a clinical trial (http://www.clinicaltrials.gov/
ct2/show/NCT00602862) involving 1week of neoadjuvant sorafenib (oral, 400 mg twice-daily) 
treatment. The time between cessation of medication and surgery was 60 h.
The gross pathology specimen showed a centrally located nodular tumour of diameter 60 mm 
that extended into the perirenal fat tissue. The tumour was yellow–white with extensive necrosis 
and focal cystic changes.
Histologically, the tumour was composed of a rhabdoid component with higher nuclear grade 
(grade 4) and a clear cell component (Figure 1A,B respectively). Treatment effects differed 
remarkably between the rhabdoid component and the non-rhabdoid ccRCC component. In 
the rhabdoid component, extensive necrosis was observed, which we propose is secondary 
to prominent damage to the tumour vasculature. Loss of endothelial function was frequently 
observed, as shown by detachment of the endothelial cells, fibrinoid necrosis, thrombus formation, 
and obliteration of the vascular lumen. The perivascular tumour tissue showed ischaemic necrosis 
with mixed inflammatory cells (Figure 1C). The non-rhabdoid ccRCC component sometimes 
showed perivascular hyalinization, which can be attributed to degeneration of the perivascular 
tumour tissue. The remaining perivascular vital tumour tissue showed clear cytoplasm, a lower 
nuclear grade, and shrinking of nuclei (Figure 1D). Immunohistochemical anti-VEGF-A staining 
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showed stronger staining of the rhabdoid component than of the clear cell component (Figures 
1E, F respectively). In a control group of five ccRCCs with rhabdoid features, randomly chosen 
from our pathology archive, we could not detect blood vessel/endothelial damage. In 5/5 
tumours, dispersed areas of necrosis could be observed in the rhabdoid components, which 
stands in contrast to the extensive necrosis observed in the current case. In 4/5 tumours, the 
rhabdoid component also showed stronger staining with anti-VEGF-A antibody than the ccRCC 
component (not shown).
Figure 1: Rhabdoid features [A, haematoxylin and eosin (HE), ×200] in otherwise typical clear cell renal cell 
carcinoma (ccRCC) (B, HE, ×200). Blood vessel damage can be seen with fibrin clot formation and accompanying 
necrosis in association with a rhabdoid tumour component (C, HE, ×50). Blood vessels are wide open, and show 
only perivascular hyalinization in the clear cell component (D, HE, ×50). Strong vascular endothelial growth 
factor-A (VEGF-A) production in the rhabdoid component of the tumour can be seen (E, VEGF-A, ×200), in contrast 
to the clear cell component (F, VEGF-A, ×200).
Our combined results suggest that the more aggressive rhabdoid component in ccRCC with 
rhabdoid features produces more VEGF-A and is therefore more susceptible to inhibition of 
VEGF-A effects by TK inhibitors. These findings indicate that the success of antiangiogenic therapy 
might be predicted on the basis of histological features of the tumour, but this should be verified 
in a larger patient population.
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Abstract
Over eighty percent of renal cell carcinomas of the clear cell type (ccRCC) constitutively secrete 
vascular endothelial growth factor-A (VEGF-A), due to a defect in the von Hippel Lindau (VHL) 
gene. These tumors are therefore highly angiogenic, making metastasized ccRCC (m-ccRCC) 
patients the prime candidates for anti-angiogenic therapy. Angiogenesis inhibition nowadays 
forms the backbone of first-line treatment of m-ccRCC patients. Despite prolongation of disease-
free and overall survival, common experience is that resistance develops.
To get more insight in the pathophysiological mechanisms that underlie disease progression 
under anti-angiogenic therapy, we extensively analyzed from a 68 year-old male m-ccRCC 
patient the primary tumor and the corresponding pulmonary metastasis that initially responded 
well to anti-angiogenic treatment, but ultimately progressed. We show that anti-angiogenic 
treatment induced a phenotypic adaptation in the lung lesion, characterized by infiltration of 
tumor cells along and even in the pulmonary vasculature, resembling pulmonary lymphangitis 
carcinomatosis. This phenotype was radiologically reflected by a cloudy pattern on CT.
These observations suggest that pulmonary metastases of renal cell carcinoma can respond 
to anti-angiogenic therapies by adopting a diffuse phenotype that allows progression in an 
angiogenesis-independent fashion through cooption.
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Introduction
Starting with the study of Hurwitz that demonstrated benefit of treatment with bevacizumab (the 
humanized anti-VEGF-A antibody) combined with chemotherapy on progression-free and overall 
survival of patients with disseminated colorectal carcinoma1, angiogenesis inhibitors have made a 
firm entry into oncology practice. The effects of bevacizumab in combination with chemotherapy 
have now been investigated in a wide range of tumor types. Although initially beneficial, almost 
without exception resistance develops. In tumor types such as adenocarcinomas of the breast 
and glioblastomas, bevacizumab failed to prolong overall survival2-4.
One of the few tumor types that is responsive to monotherapy with angiogenesis inhibitors is 
clear cell renal cell cancer (ccRCC)5. The large majority of ccRCCs have a defective Von Hippel 
Lindau gene (VHL)6,7, resulting in increased half-life and accumulation of the transcription factors 
hypoxia inducible factors HIF1α and/or HIF2α8. Because VEGF-A is one of the prototype target 
genes of HIF1α, ccRCC is highly vascularized and, indeed, responds relatively well to angiogenesis 
inhibitors. Currently, besides bevacizumab (in combination with interferon) multispecific 
inhibitors of angiogenic receptors VEGFR2 and PDGFRβ are used for first-line treatment of 
patients with m-ccRCC9. Despite the impact on progression free survival also these patients 
develop resistance, reflected by a limited effect on overall survival. Different mechanisms of 
resistance to angiogenesis inhibitors have been proposed10. One of these is a phenotypic shift to 
non-angiogenic vessel cooption, a phenomenon that can be especially expected in tissues with a 
high vessel density. Recently, vessel cooption has been demonstrated as a resistance mechanism 
in hepatic metastases of colorectal carcinoma11 and increased vessel cooption has also been 
observed in glioblastoma12.
One of the problems in studying the morphological response of metastatic lesions to anti- 
angiogenic treatment, is the scarcity of post-treatment tumor specimen. Here we report on a 
patient with metastasized renal cell carcinoma who became amenable for metastasectomy after 
treatment with the VEGFR2/PDGFRβ inhibitor cediranib.
Patient history
A 68-year-old male underwent radical tumor nephrectomy in April 1999. The histopathological 
workup of the specimen showed a pT3bN0M0 renal cell carcinoma of the clear cell type (revised 
according to WHO 2010 classification). In May 2002 metastatic disease in lung and mediastinal 
lymph nodes was diagnosed on a routine follow-up chest CT scan. IFN-α treatment was initiated 
in October 2002 and discontinued nine months later because the patient had stable disease. 
In December 2004, there was evident disease progression and the patient was enrolled in a 
phase I study (NCT00502060) in which he was treated with the combination of the angiogenesis 
inhibitor cediranib (20 mg p.o. daily), a VEGF receptor 2 (VEGFR2)- and platelet derived growth 
factor receptor (PDGFR)-inhibitor, and gefitinib (500 mg p.o. daily), an epidermal growth factor 
receptor (EGFR) inhibitor. After 4 weeks of therapy the lung metastases showed a partial response 
with tumor downsizing from 7.5 cm to 4.5 cm (Figure 1A and 1B, respectively).
6. Pulmonary lymphangitis carcinomatosis-like tumour progression after cediranib therapy 
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Figure 1
Figure 1. CT scans of a 68-year-old male patient at baseline (A, December 2004) and after 4 weeks of therapy with 
cediranib/gefitinib (B, January 2005). Note the regression of the tumour at the upper left part of the lung. This 
partial response enabled metastasectomy.
Metastasectomy followed in October 2005 after a two week drug holiday to prevent wound 
healing complications. Subsequent histopathological analysis revealed extensive infiltration of 
tumor in the lung tissue, reaching in the resection plane.
In July 2006, tumor progression was observed in the conventional thorax X-ray. Malignancy was 
confirmed in August 2006 in bronchus brush cytology material from the lower left lung. As third 
line therapy, patient was treated with the multi-target angiogenesis inhibitor sorafenib (400 
mg orally daily). During this treatment, the pulmonary lesions showed progression to a cloudy 
pulmonary lymphangitis carcinomatosis-like (PLC-like) pattern in the CT scan. In February 2007 
a high resolution CT scan (HRCT) of the chest showed a diffuse infiltrative process suggestive of 
PLC (Figure 2). The patient died in January 2008. An autopsy was not performed.
Figure 2. Chest high resolution CT (HRCT) scan of patient after sorafenib treatment. Arrow points at a region 
suspect for infiltrative growth.
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Methods
Routine thorax CT-scans were used for the evaluation of metastases. To examine the effect of 
anti-angiogenic treatment, tissue blocks from the primary ccRCC specimen and metastasectomy 
specimen were used. Immunohistochemical stainings were performed with antibodies against 
cytokeratin 7 (CK7; to detect pulmonary epithelial cells), carbonic anhydrase-IX (CA-IX; antibody 
G250, to detect tumour cells)13, CD34 (NeoMarkers, USA, to detect endothelial cells), laminin 
(DakoCytomation, Denmark, to detect vessel basement membrane), D2-40 (to stain for lymph 
vessels), α-SMA (α- smooth muscle actin, to detect pericytes, Sigma, Zwijndrecht, The Netherlands), 
Ki67 (DakoCytomation, Denmark, to detect tumour cell proliferation) and cleaved caspase 3 (BD 
Pharmingen, to detect apoptosis) essentially as described14.
Results
Histological analysis of the tumour nephrectomy specimen showed a typical ccRCC morphology 
(H&E staining in Fig 3A) with central areas of necrosis and at the tumour rim a micronodular 
phenotype with clusters of cancer cells, surrounded by endothelial cells (CD34 staining in Fig 3B), 
pericytes (α-SMA staining, Fig 3C) and basement membrane (laminin staining in Fig 3D)15. The 
tumor was homogeneously positive for carbonic anhydrase IX (CA-IX), a known marker of ccRCC16 
(not shown).
Figure 3. Morphology of the primary tumour. A characteristic clear cell phenotype is observed (H&E in A) with high 
vessel density as seen with CD34 (B), α-smooth muscle actin (C) and laminin (D) staining. Magnification x50.
6. Pulmonary lymphangitis carcinomatosis-like tumour progression after cediranib therapy 
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Figure 4
Immunohistochemical analysis of the treated metastasis is depicted in figure 4. Overall, the 
centre of the tumour was necrotic and viable tumour was present at the rim (Fig 4A). Distant 
from the main tumour mass, and throughout the entire surgically removed tissue, numerous 
small tumour deposits were observed that infiltrated the normal tissue (G250 staining for CA-IX in 
Fig 4B). Central hypoxia was observed only occasionally (determined by glut-1 expression14, not 
shown). The appearance of tumor deposits was often branched (inset in Fig 4B) suggestive of an 
association with vasculature. Further analysis revealed that tumour deposits were almost always 
localized directly adjacent to larger pulmonary arteries (α-SMA staining in Fig 4C, arrows point at 
peri-arterial tumour deposits) but association around bronchi was also frequently observed (CK7 
staining in Fig 4D). Importantly, large parts of the viable tumour mass were characterized by the 
presence of a fibrovascular network, positive for CD34 (Fig 4E), α-SMA (Fig 3F), laminin and collagen 
IV (not shown), similar to the network that is characteristically observed in primary ccRCC. In the 
treated metastasis, however, this vascular network formed a relatively open structure with large 
spaces between tumour cell clusters and vessel wall elements. In these spaces erythrocytes were 
present (Fig 4A), suggesting an intravascular localization of tumour aggregates and at least some 
degree of circulation. Tumour cells in these aggregates appeared viable. Intriguingly, a locally 
high proliferation index was observed (approximately 50%, Ki67 staining in Fig 4G), although this 
was only apparent in regions with large spaces between tumour cells and vessel wall elements. 
Fibrovascular structures in the metastasis were positive for the lymphatic endothelial marker 
D2-40 (not shown) suggestive of the presence of tumour in the lymphatic vasculature; a large 
proportion of D2-40 positive vessel structures was also CD31 and CD34 positive and associated 
with pericytes.
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Figure 4. Morphology of pulmonary post-treatment metastases. Multiple cuffs of tumour cells are detected in a 
vascular cast with H&E staining (A) and CA-IX staining (B). Inset in B shows branched tumour ‘rods’, suggestive 
of vessel association. Peri-arterial tumour localization is illustrated in α-SMA staining (C, arrows point at tumour 
cell cuffs) but frequently the tumour was also present in the wall of bronchi (CK7 staining in D). E-G represent 
immunostained sections of tumour regions, adjacent to the necrotic centre of the tumour. Note the similarity of the 
vascular architecture with that in the primary tumour (Fig 1B) whereas numerous small, apparently shrunk, tumour 
aggregates are located within a vascular cast that is CD34 (E) and α-SMA (F) positive. Note also the presence of 
erythrocytes in the spaces between tumour aggregates and vascular elements, suggestive of intravascular tumour 
localization (A). Panel G indicates relatively high proliferation via Ki67 staining in some areas. Magnification x100
Discussion
The highly angiogenic character of ccRCC, a result of constitutive VEGF-A expression, has resulted 
in therapeutic approaches that make use of VEGF pathway inhibition. The clinical implementation 
of tyrosine kinase inhibitors (TKIs) directed against VEGFR and PDGFR has considerably improved 
the prognosis of ccRCC patients17,18 yet does not prevent cancer progression in the end. In 
preclinical models of brain metastases of melanoma and orthotopic models of glioma, inhibitors 
of angiogenesis induce a shift from an expansive to an invasive growth mode in which tumor 
cells use pre-existent blood vessels (vessel cooption)19-21 and recently the clinical relevance of 
these findings has been demonstrated in liver metastases of colorectal carcinoma and breast 
adenocarcinoma under bevacizumab treatment11, as well as in glioblastoma under bevacizumab/
temozolomide treatment12. The data presented here suggest that also in other vessel-dense 
tissues such as lung, vessel cooption can be an effective way for a tumor to escape the effects of 
anti-angiogenesis. Furthermore, it appears that tumor deposits not only coopt blood vessels but 
also bronchi, which may be an alternative method for cancer cells to ensure an effective supply 
of oxygen.
This observation has important consequences. First, whereas chest CT scans suggest response to 
therapy based on the shrinkage of the bulk of tumor, small cancer cell deposits that invade the 
lung lymphatics or lung vasculature are less easily recognized on conventional CT scans. These 
deposits prohibit curative surgery. Our observation may also explain massive but reversible flare 
up of pulmonary metastases of renal cell cancers that can be observed once treatment with anti-
angiogenic drugs is terminated22. Indeed, progression of cancer in the lung via diffuse growth 
while suppressing VEGF-effects may result in a significant increase of tumor burden and high 
levels of local VEGF. Upon withdrawal of VEGF suppression, the high levels of VEGF will rapidly 
induce pleural effusion and dyspnoea and pain, which reduces upon readministration of drugs.
The patient in this study was treated in third line with sorafenib which, again, ultimately could 
not prevent tumor progression. In high resolution CT scans lymphangitis carcinomatosis was 
observed. Although no post-mortem examination was performed and no histopathological 
confirmation is available, the CT scans in Figure 2 also strongly suggest extensive tumor infiltration 
in the lung, although with a different phenotype than the “cannon ball metastases”; large, round 
and sharply demarcated lesions, that are normally observed for renal cell cancer metastases in 
lung23.
6. Pulmonary lymphangitis carcinomatosis-like tumour progression after cediranib therapy 
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Pulmonary lymphangitis carcinomatosis is rarely seen in m-ccRCC, but has been described more 
often in the context of angiogenesis inhibition22. Because we did not have pre-treatment HRCT 
scans available, it is difficult to attribute the development of this phenotype to the cediranib or 
sorafenib treatment.
In this report we describe for the first time using extensive (immuno)histopathology and 
radiology that pulmonary metastastes of renal cell cancer can adapt to anti-angiogenic treatment 
by vessel and bronchus cooption. As this report is based on one patient, expanding this work to 
other similar cases to find validation of our findings is important, but also difficult because post-
treatment metastastic cancer samples are scarce. Still, the biological concept of vessel cooption 
as a mechanism of resistance to angiogenesis inhibitors has already been demonstrated in 
preclinical models and in patients, giving credibility to our findings.
Conflicts of interest: none of the authors have competing interests to declare.
83  
References
Hurwitz, H., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal 
cancer. N Engl J Med 350, 2335-2342 (2004).
Miller, K., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J 
Med 357, 2666-2676 (2007).
Chinot, O.L., Wick, W. & Cloughesy, T. Bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370, 
2049 (2014).
Gilbert, M.R., Sulman, E.P. & Mehta, M.P. Bevacizumab for newly diagnosed glioblastoma. N Engl J Med 
370, 2048-2049 (2014).
Guo, M., Cao, Y., Yang, J. & Zhang, J. A comparison of drug resistances of targeted drugs for advanced 
renal cell cancer approved by the Food and Drug Administration: A meta-analysis of randomized clinical 
trials. J Cancer Res Ther 12, 109-115 (2016).
Banks, R.E., et al. Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and 
relationship with clinical variables in sporadic renal cancer. Cancer Res 66, 2000-2011 (2006).
Harris, A.L. von Hippel-Lindau syndrome: target for anti-vascular endothelial growth factor (VEGF) 
receptor therapy. The oncologist 5 Suppl 1, 32-36 (2000).
Kaelin, W.G., Jr. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin 
Cancer Res 13, 680s-684s (2007).
Rousseau, B., et al. First-line antiangiogenics for metastatic renal cell carcinoma: A systematic review and 
network meta-analysis. Crit Rev Oncol Hematol 107, 44-53 (2016).
Bergers, G. & Hanahan, D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8, 592-603 
(2008).
Frentzas, S., et al. Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases. Nat 
Med 22, 1294-1302 (2016).
Verhoeff, J.J., et al. Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. 
BMC Cancer 9, 444 (2009).
Sandlund, J., et al. Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. 
BJU Int. 100, 556-560. Epub 2007 Jul 2003. (2007).
Roodink, I., et al. Development of the tumor vascular bed in response to hypoxia- induced VEGF-A differs 
from that in tumors with constitutive VEGF-A expression. Int J Cancer. 119, 2054-2062. (2006).
Kats-Ugurlu, G., et al. Circulating tumour tissue fragments in patients with pulmonary metastasis of clear 
cell renal cell carcinoma. J Pathol 219, 287-293 (2009).
Benej, M., Pastorekova, S. & Pastorek, J. Carbonic anhydrase IX: regulation and role in cancer. Sub-cellular 
biochemistry 75, 199-219 (2014).
Ward, J.E. & Stadler, W.M. Pazopanib in renal cell carcinoma. Clinical cancer research : an official journal of 
the American Association for Cancer Research 16, 5923-5927 (2010).
Calvo, E., Schmidinger, M., Heng, D.Y., Grunwald, V. & Escudier, B. Improvement in survival end points of 
patients with metastatic renal cell carcinoma through sequential targeted therapy. Cancer treatment 
reviews 50, 109-117 (2016).
Leenders, W.P., Kusters, B. & de Waal, R.M. Vessel co-option: how tumors obtain blood supply in the 
absence of sprouting angiogenesis. Endothelium 9, 83-87 (2002).
Leenders, W.P., et al. Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor 
progression via vessel co-option. Clin Cancer Res 10, 6222-6230 (2004).
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
6. Pulmonary lymphangitis carcinomatosis-like tumour progression after cediranib therapy 
 84 
Navis, A.C., et al. Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models. 
J Pathol 223, 626-634 (2011).
Desar, I.M., et al. The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or 
sorafenib in renal cell cancer patients. A report of three cases. Acta Oncol 48, 927-931 (2009).
Chao, C.M. & Lai, C.C. Cannon ball pulmonary metastases. QJM : monthly journal of the Association of 
Physicians 108, 843 (2015).
21
22
23
85  
 86 
87  
7
Summarizing discussion and 
future perspectives
 88 
89  
7. Summarizing discussion and future perspectives
Summarizing discussion
Tumor biology studies focus on better understanding of the carcinogenic process, including 
morphological aspects and genetic alterations within the primary tumor, mechanisms involved 
in the metastatic process and morphological and genetic characteristics of metastastic lesions. 
Unraveling these complex relations can lead to the discovery of better diagnostic tools and new 
therapeutic targets.
Cancer is a disease that spreads throughout the body through a complex process with multiple 
components where each of these components plays a complementary role. The neoplastic cell 
itself, the stromal components within and around the primary tumor, inflammation, immunological 
factors, angiogenesis and characteristics of the metastastic niche are important for the survival of 
metastazing tumor-cells or -tissues.
The most widely accepted concepts of metastasis are the seed and soil hypothesis of Paget and 
the more recent epidermal-mesenchymal transition concept of Hay. In both concepts metastasis 
takes place as the result of a complex sequence of events, including migration of tumor cells 
through stroma, proteolytic degradation of stromal and vessel wall elements, intravasation, 
transport through circulation, extravasation and outgrowth at compatible sites in the body.
More recent studies suggest that a novel invasion-independent (protease-independent) 
hematogenous sequence of events can also lead to metastasis. In this thesis we focus on this 
new metastatic pathway in relation to VEGF-A expression in a subcutaneous xenograft model of 
melanoma in mice and in clinical clear cell renal cell carcinoma (ccRCC).
Micronodular tumor phenotype in subcutaneous xenografts in mice
In chapter 2, the characteristic phenotype of subcutaneous tumors that grew in the flank of 
nude mice after injection of the human melanoma cell line Mel57 is discussed. This cell line was 
transfected with cDNA encoding VEGF-A (Vascular Endothelial Growth Factor A) which results in 
constitutive and high production of the protein. In comparison to the tumors without VEGF-A 
production, these tumors grew much faster and showed a strikingly different phenotype than 
tumors grown from the parental line. They were composed of multiple micronodules, that were 
surrounded by a laminin-network, endothelial cells and pericytes and which was defined as the 
micronodular phenotype. Another characteristic of this phenotype is the presence of sinusoidal 
blood vessels in the vicinity of tumor where micronodules bulge into the blood vessels with an 
endothelial cell layer outside and a pericyte layer inside surrrounding a micronodule as shown 
by immunohistochemical staining. This finding is consistent with an earlier described model of 
bulging by Sugino et al. According to this model, bulging tumor nodules become gradually covered 
by vessel wall elements and can lose contact with the vessel wall to become tumor-emboli. To 
test whether VEGF-A enhances the occurrence of lung metastasis as a result of enhanced tumor-
emboli formation, Mel57-VEGF-A and Mel57- EGFP (Enhanced Green Fluorescent Protein) tumor 
cells were inoculated in contralateral flanks of immunocompromised mice and the occurrence of 
lung lesions was studied. Remarkably, more than 90% of the metastatic lung lesions were derived 
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from the Mel57-VEGF-A xenograft. These tumor clusters were always localized within the larger 
branches of pulmonary arteries strongly suggesting that they originated as tumor emboli. Thus, 
VEGF-A enhanced spontaneous metastasis by inducing intravasation of heterogeneous tumor 
cell clusters, surrounded by vessel wall elements, via an invasion-independent mechanism.
Effect of tyrosine kinase inhibitor zd6474 on the micronodular phenotype and lung metastases
When tyrosine kinase inhibitor (TKI) vandetanib (ZD6474, an inhibitor of vascular endothelial 
growth factor receptor 2 [VEGFR2] and epidermal growth factor receptor [EGFR]) was administered 
8 days after tumor inoculation, the xenografted Mel57-VEGF-A tumors still showed the nodular 
phenotype, albeit less pronounced, and the nodules were devoid of endothelial cell coverage. 
ZD6474 slowed down outgrowth of the tumors to growth rates that are comparable to EGFP-
control xenografts. No metastases were found in treated mice, in contrast to the placebo controls 
(mean number of tumors N=16). However, when vandetanib treatment was started 4 weeks after 
tumor inoculation the metastatic burden in the lungs was comparable with that of Mel57-VEGF-A 
tumors without treatment. This strongly suggests that the metastatic process starts already in the 
early phases of the tumor development parallel to the local outgrowth of the tumor.
The striking similarities between the experimental angiogenic melanoma xenograft model and 
ccRCC regarding VEGF-A expression, tumor morphology and metastastic behavior prompted 
studies investigating whether formation and shedding of tumor tissue fragments into the 
circulation has a human counterpart in ccRCC patients.
Micronodular tumor phenotype, presence of tumor cell clusters in renal venous perfundate 
and lung metastastasis in clinical ccRCC
ccRCC can be seen as a prototypical tumor type for the invasion-independent hematogenous 
metastatic pathway due to its constant and high VEGF-A production as a result of VHL gene 
aberrations (mutations and promoter silencing by methylation) commonly observed in these 
tumors.
For this study only patients who underwent a radical tumor nephrectomy were included. After 
perfusion of the renal arteries, perfundate from the renal vein was collected postoperatively 
for the detection of tumor emboli. Clinical and radiological studies were used to evaluate the 
presence of pulmonary metastasis. 14 of the 42 patients available for analysis (33%) had tumor 
cell clusters (TCC) in the venous outflow perfundate. In 4 of the 14 cases TCC were partially or 
completely covered by endothelial cells and pericytes.
Synchronous pulmonary metastases were present in 12/14 patients in whom TCC were observed 
and 2 patients developed pulmonary metastases later. In contrast, 21 of the remaining 28 patients 
without tumor emboli did not develop lung metastasis after 1 year of follow-up. The micronodular 
phenotype defined as presence of micronodular growth somewhere in the tumor was observed 
in 31/42 tumors and in 11 (35%) of patients with tumors with this phenotype TCC were recovered 
in the renal venous outflow. In contrast, in 8 of the 11 patients without micronodular phenotype 
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in their tumor, shed TCC were not detected in the renal venous outflow (72%). Thus, there was 
a significant correlation between the presence of tumor cell clusters recovered in renal venous 
outflow, the occurrence of pulmonary metastasis and the presence of a micronodular phenotype 
in the primary tumor.
Based on these findings it was hypothesized that disruption of the micronodular phenotype 
through inhibition of VEGF signaling may result in reduced shedding of tumor cell clusters from 
the primary tumor and improved overall survival by preventing entrance of new tumor cell 
fragments into the circulation.
Effects of 4 weeks of neoadjuvant Sorafenib treatment on primary ccRCC phenotype, renal 
venous tumor cell clusters and survival
In chapter 4, 10 patients with a renal tumor who received 4 weeks of neoadjuvant Sorafenib 
treatment were studied by collecting perfundate from postnephrectomy specimen, macroscopic 
sampling of rest tumor including necrotic areas and microscopic examination using additional 
immunohistochemical stainings and evaluation of overall survival of these patients. Sorafenib 
is a tyrosine-kinase inhibitor directed against VEGF receptor, platelet derived growth factor 
receptor tyrosine kinases and RAF kinase and regarded as an anti-angiogenic drug that can be 
prescribed to patients with metastatic RCC. 8 patients were diagnosed with ccRCC-type based on 
pathology. The findings in these tumors such as effects of treatment on primary tumor, presence 
of tumor cell groups in the perfundate and effect of neoadjuvant sorafenib treatment on survival 
were compared with a control group from the earlier study described in chapter 3 matched 
for prognostic factors. As expected, sorafenib treatment destroyed the tumor vasculature and 
prevented formation of new blood vessels consequently resulting in the destruction of the 
micronodular tumor phenotype but some vital tumor parts persisted. The tumors frequently 
showed prominent edema and fibrinoid necrosis of the blood vessel walls. The endothelial lining 
of the vessels was often discontinuous with fragmentation of the endothelial cells and sometimes 
thrombus formation. Importantly, the vascular changes induced after 4 weeks of neoadjuvant 
sorafenib treatment were tumor specific since vessels in normal renal tissue distant from the 
tumors showed a normal appearance as well as the vessels in the tumors of the control group.
Unexpectedly, small TCC were found in the venous blood perfundate in 6 of the 8 patients. 
Endothelial cell lining of basal membrane elements was not detected whereas this lining 
was observed in 30% of the clusters from the control group. In treated tumors, intratumoral 
lymphocyte densities were higher than in control groups. Very high densities of lymphocytes 
were consistently associated with fibrovascular structures and damaged tumor vasculature, 
whereas nontreated ccRCC showed limited lymphocytic infiltrates mainly concentrated at the 
tumor rim. Kaplan Meier analysis showed significantly poorer overall survival of patients in the 
neoadjuvant group (n=7) compared those of the matched control group (n=12).
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Effect of 1 week of neoadjuvant Sorafenib treatment on the different components of ccRCC 
with rhabdoid features
ccRCC with rhabdoid features accounts for approximately 5% of all ccRCC and is defined as 
high grade and aggressive. In chapter 5 histological changes observed in a tumor nephrectomy 
specimen of a single case of ccRCC with rhabdoid features after 1 week of neoadjuvant sorafenib 
treatment is described. These histological changes are compared with the histological findings 
of 5 archival ccRCC with rhabdoid features. In the tumor recovered from the patient treated 
with sorafenib, the rhabdoid component showed endothelial cell damage with detachment 
of the endothelial cells, fibrinoid necrosis, thrombus formation and obliteration of the vascular 
lumen. Secondary to prominent damage of the tumor vasculature there was extensive necrosis. 
The perivascular tumor tissue showed ischemic necrosis with mixed inflammatory cells. The 
non-rhabdoid ccRCC component sometimes showed perivascular hyalinization. Additional 
immunohistochemical staining showed stronger expression of VEGF-A in the rhabdoid 
component in comparison to the ccRCC component within the same tumor.
In the control group dispersed areas of necrosis were present but not as extensive as tumor 
from the sorafenib-treated patient and blood vessel/endothelial damage was absent. These 
results suggest that the more aggressive rhabdoid component of ccRCC with rhabdoid features 
produces more VEGF-A and is therefore more susceptible to angiogenesis inhibition.
Pulmonary lymphangitic carcinomatosis of clear ccRCC after angiogenesis inhibition
In chapter 6 an unusual pulmonary lymphangitis carcinomatosis metastatic pattern is described 
in a patient in whom ccRCC was diagnosed after tumor nephrectomy. After stabilization of the 
pulmonary metastasis under interferon therapy, follow-up showed a large, unresectable, solitary 
pulmonary metastasis.
CT images showed downsizing of the lesion upon treatment with erlotinib and gefitinib allowing 
metastasectomy. In the surgical specimen two growth patterns were seen: a nodular pattern with 
extensive central necrosis and vital tumor with an infiltrative component in close contact with the 
pre-existent larger blood vessels and bronchi. Tumor clusters in the lung were covered with vessel 
wall elements comparable to those described earlier in the invasion-independent VEGF-A related 
hematogenous metastasis. Also tumor associated blood vessel elements were scattered in the 
fibrovascular stroma with dual expression of the blood vessel endothelial markers CD34/CD31 
and the lymphendothelial marker D2-40. The infiltrative component showed a cloudy metastatic 
pattern in the CT scan.
The findings suggest that metastatic ccRCC can respond to anti-angiogenic therapy by adopting 
a diffuse, infiltrative phenotype which allows it to progress in an angiogenesis independent way.
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Future perspectives
In this era of personalized medicine expectations of turning metastatic cancer into a chronic 
disease is a reality only for a minority of patients. Recent knowledge about tumor heterogeneity 
within primary tumor and/or metastasis, challenges clinicians to use additional single or combined 
targeted therapy in patients with metastatic disease1.
New methods are needed to monitor and characterize tumor cell and/or its genetic component 
in circulation to be able to adjust treatment plans in these patients.
One of these methods is monitoring number of circulating tumor cells (CTC) in blood of patients 
before, during and after treatment2-7. With new techniques in molecular biology, genetic 
alterations can be detected in CTC. These mutations can represent very small clones originating 
from the primary tumor or represent the emergence of clones with new mutations after 
treatment8. Another method to study genetic characteristics of tumor cells is to use circulating 
tumor DNA (ctDNA) in blood. ctDNA enters the circulation through necrosis or apoptosis of 
tumor cells. Long DNA fragments result from tumor necrosis and small DNA fragments (<200 bp) 
result from apoptosis9.
Recently, the FDA approved the use of the CellSearch system in patients with prostate-, breast- 
and colon cancer with this aim10. The CellSearch system uses ferrofluid magnetic nanoparticles 
coupled to epithelial cell-specific antibodies to recognize and isolate circulating tumor cells from 
whole blood, allowing for enrichment of tumor cells by a noninvasive clinical procedure11.
The CellSearch system collects besides circulating tumor cells also circulating tumor fragments 
(CTF)/tumor cell clusters (TCC)/circulating tumor emboli (CTE)8,12 from blood.
According to the CellSearch system a tumor cell cluster is a group of CTCs containing three 
or more cells expressing Epithelial Cell Adhesion Molecule (EpCAM) and cytokeratins without 
expression of CD45 and have (4’,6-diamidino-2-phenylindole)- stained nuclei13. There are different 
theories about how TCC are formed; one of these is that TCC crumble from a tumor thrombus in 
a blood vessel, another one is that CTC aggregate intravascularly once they are in circulation and 
according to a more recent one TCC arise from oligoclonal tumor cell groupings and not from 
intravascular aggregation events8.
Composition of CTC, ctDNA and TCC differ from each other and each has its own advantages/ 
disadvantages regarding collection and prognostic/predictive values. All three can be obtained 
from blood samples. Only small amounts are needed to carry out molecular studies (ctDNA 
for example often represents <1.0% of total circulating cell-free DNA)14. CTC and ctDNA are 
more ubiquitous in the circulation and have a longer half-life compared to TCC15. Repeated 
measurements of CTC and ctDNA are needed to monitor patients for tumor progression and 
resistance to therapy. In case of a known genetic background of primary tumor, collection of 
CTC or ctDNA with a different genetic profile in peripheral blood can give information about 
an undetected small clone in the primary tumor or evolving/already metastatic disease with a 
7. Summarizing discussion and future perspectives
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different genetic profile compared to the primary tumor. High baseline measurements of CTC 
or ctDNA in peripheral blood under therapy may be indicative for therapy resistance. In this case 
therapy can be changed based on genetic profiling of CTC or ctDNA.
TCC are composed not only of tumor cells but also contain the stromal components between 
tumor cells. The first circulating TCC have already been recognized in the 1950s16. Later their 
scarcity in circulation but obviously increased metastatic potential was reported repeatedly17,18. In 
recent years CTF/CTE/TCCs have been identified besides CTCs in studies conducted on epithelial 
tumors18-20.
TCC have proven prognostic/predictive value, especially in ccRCC patients21. Their shorter time 
in circulation and difficulties in harvesting TCC from blood make it difficult to implement their 
use in standard patient care. The lack of Epcam on the surface of the majority of ccRCC make 
the use of the CellSearch problematic in the setting of ccRCC. However adjusting the CellSearch 
with for instance anti-CAIX (Carbonic Anhydrase IX) antibody, recognizing a cell surface molecule 
highly expressed on almost all ccRCC tumors can be an alternative way of using an already 
proven method. Implementing perfusion techniques of postoperative resection specimen like 
the one described in this thesis based on the collection of TCC of a certain cell size, can provide 
extra prognostic/predictive information. If there is already a metastatic disease at the time of 
nephrectomy genetic profiling of TCC may help in making choices for the treatment plan.
Targeted therapy can be helpful in tumor downsizing of ccRCC and it can increase progression 
free survival significantly, however the effect on overall survival is very limited. Recent studies 
focus on new targets like Hypoxia Inducible Factor (1α, 1β of 2α)22 and monoclonal antibodies 
against CAIX23 aiming to target ccRCC from different angles. Emerging data on differences 
between metabolic characteristics of primary ccRCC and metastases point toward other possible 
targets opening a whole new dimension24. Still more druggable targets are being identified in 
primary tumors and metastatic lesions through the use of highly advanced molecular methods.
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8. Samenvatting en toekomstperspectief
Nederlandse samenvatting
Studies over tumor biologie concentreren zich op het beter inzicht krijgen in het proces van 
carcinogenese, inclusief de morfologische aspecten en de genetische veranderingen binnen 
de primaire tumor, de mechanismen waarop het metastatische proces is gebaseerd en de 
morfologische en genetische kenmerken van de metastatische laesies. 
Kanker is een ziekte die zich verspreidt door het lichaam door een complex proces met meerdere 
componenten die een complementaire rol spelen. De neoplastische cel zelf, de stromale 
componenten binnen en rondom de primaire tumor, ontsteking, immunologische factoren, 
angiogenese en de kenmerken van de metastatische niche zijn belangrijk voor het overleven van 
de tumorcellen of tumorweefsels die uitzaaien.
De meest geaccepteerde concepten van metastasering  zijn  ‘the seed and soil hypothesis’ van 
Paget en het recentere ‘Epidermal-mesenchymal  transition concept’ van Hay. In beide concepten 
is  een uitzaaiing het resultaat van een complexe reeks van gebeurtenissen inclusief migratie van 
tumorcellen door het stroma, proteolytische degradatie van de stromale- en vaatwandelementen, 
intravasatie, transport door de circulatie, extravasatie en uitgroei op de compatibele sites in het 
lichaam.
De recentere studies suggereren dat een nieuwe, invasie-onafhankelijke (protease-onafhankelijke) 
hematogene reeks van gebeurtenissen ook kan leiden tot een metastase. In dit proefschrift 
focussen wij ons op deze nieuwe vorm van hematogene metastasering in relatie tot de VEGF-A 
expressie in een subcutaan xenotransplantaat model van melanoom in muizen en in het klinische 
heldercellig nier cel carcinoom (ccRCC).
Micronodulair tumor fenotype in de subcutane xenotransplantaten in muizen
In hoofdstuk 2  is het karakteristieke fenotype van de subcutane tumoren bediscussieerd die in de 
flank van de naakte muizen groeiden na injectie van de humane melanoom cellijn Mel57. Deze 
cellijn was getransfecteerd met cDNA dat VEGF-A (Vasculair Endothelial Groeifactor) codeert 
waardoor dit eiwit constant en hoog geproduceerd kan worden. In vergelijking met de tumoren 
die geen VEGF-A produceren, groeien deze tumoren sneller en tonen een sterk verschillend 
fenotype. De VEGF-A producerende tumoren waren opgebouwd uit meerdere micronodules die 
omringd waren door een netwerk van laminine, endotheliale cellen en pericyten; dit fenotype 
werd gedefinieerd als het micronodulaire fenotype. Een ander kenmerk van dit fenotype is 
de aanwezigheid van sinusoidale bloedvaten in de nabijheid van de tumor met protrusie van 
micronodules in de bloedvaten die omringd worden met een endotheliale cellaag aan de 
buitenkant en een pericytenlaag aan de binnenkant, conform het eerder beschreven ‘model 
of bulging’ door Sugino et al. Volgens dit model worden de tumor nodules die protrusie tonen 
geleidelijk omringd door de vaatwandelementen tot hun verlies van binding met de vaatwand en 
het vormen van tumor-emboli. Om te testen of VEGF-A het aantal longmetastasen vermeerdert 
door formatie van een toegenomen aantal  tumor-emboli, werden Mel57-VEGF-A en Mel57-EGFP 
(Enhanced Green Fluorescent Protein) tumorcellen geïnjecteerd in de contralaterale flanken van 
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de immuun gecompromitteerde naakte muizen en werd het vóórkomen van de longlaesies 
bestudeerd. Opvallend was dat 90% van de alle pulmonale metastasen afkomstig waren uit 
het Mel57-VEGF-A xenotransplantaat. Deze clusters van tumorcellen waren altijd gelokaliseerd 
binnen de grotere vertakkingen van de pulmonale arteriën, sterk suggestief voor hun origine 
als tumoremboli. VEGF-A vermeerderde dus spontane metastasering door het induceren van de 
intravasatie van heterogene clusters van tumorcellen omringd door vaatwandelementen door 
een invasie-onafhankelijke mechanisme.
Het effect van de tyrosinase kinase inhibitor zd6474 op het micronodulaire fenotype en 
longmetastasen
Indien de tyrosine kinase inhibitor (TKI) vandetanib (ZD6474, een inhibitor van vascular endothelial 
growth factor receptor 2 [VEGFR2] en epidermal growth factor receptor [EGFR]) 8 dagen na de 
injectie van de tumorcellen werd toegediend, dan toonden de xenotransplantaat Mel57-VEGF-A 
tumoren nog steeds het nodulaire fenotype, echter in een mindere mate en zonder een omringde 
endotheliale cellaag. ZD6474 heeft de groei van de tumoren vertraagd tot groeisnelheden die 
vergelijkbaar zijn met die van EGFP-control xenotranplantaten. Er werden geen metastasen 
gevonden in de behandelde muizen, in tegenstelling tot de placebo controles (gemiddeld aantal 
tumoren n=16). Echter, indien de behandeling met vandetanib 4 weken na de tumorinjectie was 
begonnen, dan was de hoeveelheid metastatisch weefsel in de longen vergelijkbaar met die 
van de Mel57-VEGF-A tumoren zonder behandeling. Deze bevinding suggereert sterk dat het 
metastatische proces in de vroege fases van het ontwikkelen van de tumor tegelijk met de lokale 
doorgroei van de tumor begint.
De sterke gelijkenissen tussen het experimentele angiogeen melanoom xenotransplantaat model 
en klinisch ccRCC ten aanzien van de productie van VEGF-A, morfologie van de tumor en het 
metastatische gedrag hebben geleid tot de studies die onderzoeken of formatie en loslating van 
tumorweefselfragmenten in de circulatie een humane equivalent heeft in patiënten met ccRCC. 
Micronodulair tumor fenotype, aanwezigheid van de tumorcelclusters in renale veneuze 
uitstroom perfundate en longmetastasen in klinische ccRCC
CcRCC kan als een prototypisch tumortype gezien worden voor de invasie onafhankelijke 
hematogene metastasering, vanwege de constante en hoge VEGF-A productie ten gevolge 
van de VHL gen afwijkingen (mutaties en silencing van de promoter door methylatie) die vaak 
worden gezien in deze tumoren.
In deze studie waren uitsluitend patiënten geïncludeerd die een radicale tumornefrectomie 
ondergingen. Postoperatief werd het nefrectomiepreparaat geperfundeerd via de arteria renalis 
en het veneuze uitstroom perfundaat werd verzameld voor onderzoek naar tumoremboli. 
Klinische en radiologische studies werden verricht om de aanwezigheid van de pulmonale 
metastasen te evalueren. Van de 42 patiënten die geïncludeerd konden worden hadden 14 (33%) 
clusters van tumorcellen (TCC)  in het veneuze uitstroom perfundaat. In 4 van de 14 patiënten 
waren TCC partieel of totaal omringd door endotheliale cellen en pericyten.
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Synchrone pulmonale metastasen waren aanwezig in 12 van de 14 patiënten bij wie TCC 
gevonden werden en 2 van de patiënten hebben later metastasen gekregen. Daarentegen 
ontwikkelden 21 van de overige 28 patiënten zonder tumoremboli in het veneuze uitstroom 
perfundaat geen pulmonale metastasen na 1 jaar follow-up. Het micronodulaire fenotype, 
gedefinieerd als het ergens in de tumor vóórkomen van micronodulaire groei, werd gezien in 31 
van de 42 patiënten en in 11 (35%) van de patiënten met dit fenotype werden TCC gevonden in 
het perfundaat. Daarentegen werden er in 8 van de patiënten noch het micronodulaire fenotype 
noch de tumoremboli gevonden (72%). Derhalve was er een significante correlatie tussen de 
aanwezigheid van de TCC afkomstig uit het veneuze uitstroom perfundaat, het vóórkomen van 
pulmonale metastasen en de aanwezigheid van het micronodulaire fenotype in de primaire 
tumor.
Gebaseerd op deze bevindingen werd de volgende hypothese geformuleerd: beschadiging van 
het micronodulaire fenotype door inhibitie van de VEGF-A signalering kan leiden tot verminderde 
loslating van de TCCs van primaire tumoren en een verbeterde overleving van patiënten door het 
voorkomen dat nieuwe tumorcelfragmenten toegang krijgen tot de circulatie. 
Effecten van 4 weken neoadjuvante behandeling met Sorafenib op het primaire fenotype van 
ccRCC, renale veneuze tumorcelclusters en totale overleving
In hoofdstuk 4 hebben we 10 patiënten met een niertumor bestudeerd die 4 weken lang 
neoadjuvante behandeling met Sorafenib gekregen hebben. We hebben het veneuze 
uitstroom perfundaat verzameld van de postnefrectomiepreparaten, extra sampling verricht 
van de resttumor, inclusief de necrotische gebieden, microscopisch onderzoek verricht ook met 
aanvullende immunohistochemische kleuringen en de totale overleving van deze patiënten 
geëvalueerd. Sorafenib is een tyrosine kinase remmer (TKI) tegen de VEGF receptor, platelet derived 
growth factor receptor tyrosine kinases en RAF kinase, en wordt gezien als een anti-angiogeen 
middel dat voorgeschreven kan worden aan patiënten met een uitgezaaid RCC. Het heldercellige 
type van RCC werd in 8 van de patiënten gediagnosticeerd door het histopathologische 
onderzoek. De bevindingen in deze tumoren zoals de effecten van de behandeling op 
de primaire tumor, aanwezigheid van clusters van tumorcellen in het veneuze uitstroom 
perfundaat, en het effect van de neoadjuvante behandeling met sorafenib  op de overleving 
werden vergeleken met een controle groep gekozen met vergelijkbare prognostische factoren 
gebaseerd op de histopathologische kenmerken. Zoals verwacht, beschadigde de behandeling 
met sorafenib de vasculatuur van de tumor, en voorkwam het dat nieuwe bloedvaten werden 
gemaakt waardoor het micronodulaire fenotype van de tumor werd vernietigd; echter waren 
er verspreid focale gebieden met resttumor. Het tumorweefsel toonde vaak prominent oedeem 
en fibrinoide necrose van de bloedvatwand. De endotheliale bekleding van de vaatwanden was 
vaak discontinu met fragmentatie van de endotheliale cellen en soms was er thrombosering. Van 
belang waren de tumor-specifieke vasculaire veranderingen die geïnduceerd waren na 4 weken 
neoadjuvante behandeling met sorafenib. De vaten toonden een normaal aspect in het normale 
nierparenchym, gelegen ver van de tumor, evenals die in de tumoren van de controle groep.
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Onverwacht vonden we kleine TCC in het veneuze uitstroom perfundaat in 6 van de 8 
patiënten. Er werd geen endotheliale bekleding gevonden rondom of binnen de TCC, ook al 
was dit wel het geval in 4 van de 14 patiënten in de controle groep waarbij TCC gevonden 
werden. In de behandelde tumoren was de densiteit van intratumorale lymfocyten hoger dan 
in de controlegroep. De hele hoge densiteit van de lymfocyten was vaak geassocieerd met de 
fibrovasculaire structuren en de beschadigde vasculatuur van de tumor, in tegenstelling tot niet-
behandeld ccRCC  met beperkte infiltratie door de lymfocyten, die met name geconcentreerd 
gelegen waren in de periferie van de tumor. De Kaplan-Meier analyse toonde een significant 
slechtere overleving van de patiënten in de neoadjuvante groep (n=7) in vergelijking met de 
patiënten in de controlegroep met vergelijkbare histopathologische prognostische kenmerken 
(n=12).
Het effect van 1 week neoadjuvante behandeling met Sorafenib op de heldercellige en de 
rhabdoide component van ccRCC met rhabdoide kenmerken
Circa 5% van alle ccRCC toont rhabdoide kenmerken en deze onderdelen van het ccRCC zijn 
beschreven als hooggradig en agressief. In hoofdstuk 5 wordt het verschil in de histologische 
respons na 1 week voorbehandeling met sorafenib bestudeerd in een nefrectomiepreparaat 
met ccRCC met rhabdoide kenmerken. Deze histologische veranderingen werden vergeleken 
met de histologische bevindingen in 5 andere patiënten uit het archief met ccRCC met 
rhabdoide kenmerken zonder voorbehandeling. In de tumor van de patiënt die voorbehandeld 
werd met sorafenib toonde de rhabdoide component beschadiging van de endotheliale 
cellen met loslating, fibrinoide necrose, trombusvorming en de obliteratie van het vasculaire 
lumen. De tumor toonde uitgebreide necrose ten gevolge van de prominente beschadiging 
van de vasculatuur. Het perivasculaire tumorweefsel toonde ischemische necrose met een 
gemengdcellig ontstekingsinfiltraat. De non-rhabdoide component van het ccRCC toonde soms 
perivasculaire hyalinisatie. In de aanvullende immunohistochemische VEGF-A-kleuring was er 
een sterker expressiepatroon van VEGF-A in de rhabdoide component dan in de non-rhabdoide 
ccRCC component binnen dezelfde tumor.
In de controlegroep werden verspreid gebieden met necrose gevonden maar de necrose was 
niet zo uitgebreid als die van de tumor van de patiënte die voorbehandeld was met sorafenib en 
bovendien was er geen beschadiging van bloedvaten of endotheel. 
Pulmonale lymfangitis carcinomatosa van het ccRCC na inhibitie van de angiogenese
In hoofdstuk 6 wordt een ongebruikelijk metastaseringspatroon beschreven met het beeld van 
pulmonale lymfangitis carcinomatosa in een patiënt met in de voorgeschiedenis ccRCC  in een 
nefrectomiepreparaat. Er werd stabiele ziekte geconstateerd onder de interferon behandeling. 
In de follow-up werd er een grote, niet te reseceren solitaire pulmonale metastase gezien in de 
beeldvorming.
De patiënt kreeg behandeling met erlotinib en gefitinib en deze behandeling leidde tot het kleiner 
worden van de tumor op de CT-beelden waardoor metastasectomie kon worden uitgevoerd. 
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In het longpreparaat toonde de tumor twee histologische groeipatronen; een nodulair patroon 
met uitgebreide centrale necrose en een infiltratief patroon van de vitale tumor in nauwe relatie 
met de pre-existente grotere bloedvaten en bronchiën. De tumor clusters in de longen waren 
omringd door de vaatwandelementen vergelijkbaar met die eerder beschreven in het kader 
van de invasie onafhankelijke, VEGF-A-gerelateerde hematogene metastasering. Ook waren er 
tumor gerelateerde vaatwand elementen verspreid in het fibrovasculaire stroma met een  duale 
expressie van de bloedvat endotheliale markers CD34/CD31 en de lymfoendotheliale marker D2-
40.  Op de CT-scan toonde de infiltratieve component een wolkig metastatisch patroon.
Deze bevindingen suggereren dat gemetastaseerd ccRCC kan responderen op behandeling met 
anti-angiogenese door een diffuus en infiltratief groeipatroon te adopteren. Dit groeipatroon 
zorgt voor de angiogenese onafhankelijke, progressieve groei van de tumor.
8. Samenvatting en toekomstperspectief
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Toekomstperspectief
In dit tijdperk van gepersonaliseerde behandeling is het maar voor een kleine groep van patiënten 
de realiteit dat hun uitgezaaide kanker een chronische ziekte is geworden door hun specifieke 
behandeling. De huidige informatie over de heterogeniteit binnen de primaire tumoren en/of de 
metastase(n) vragen van de clinici dat zij meer onderzoeken laten verrichten naar de tumor om 
een aanvullende enkele of gecombineerde doelgerichte-therapie te gebruiken in patiënten met 
een gemetastaseerde ziekte.
Het is noodzakelijk dat er nieuwe methoden komen om de tumorcel en/of de genetische 
component hiervan te monitoren of te kunnen karakteriseren in de circulatie om de 
behandelingsplannen beter te kunnen bijstellen.  
Een van deze methoden is het monitoren van het aantal circulerende tumorcellen (CTC) in 
het bloed van de patiënten voor, tijdens en na de behandeling. Dankzij nieuwe technieken in 
moleculaire biologie kunnen genetische veranderingen gedetecteerd worden in de CTC. Deze 
mutaties kunnen de hele kleine klonen representeren die oorspronkelijk uit de primaire tumor 
komen of nieuwe klonen die ontstaan door mutaties na de behandeling. Een andere manier 
om de genetische kenmerken van tumorcellen te bestuderen is door het gebruikmaken van het 
circulerende tumor DNA (ctDNA). Het ctDNA komt in de circulatie terecht door de necrose of de 
apoptose van de tumorcellen. De lange DNA-fragmenten komen uit tumor necrose en de kleine 
DNA fragmenten (<200 bp) komen uit apoptose.
Recent heeft de FDA het gebruik van het CellSearch systeem goedgekeurd in patiënten met 
prostaat-, borst- en colonkanker. Het CellSearch system gebruikt ferrofluid magnetische 
nanoparticles gepaard aan specifieke antilichamen tegen epitheliale cellen om de circulerende 
tumorcellen te herkennen en te isoleren uit het bloed, waardoor verrijking van de tumorcellen 
plaatsvindt. 
Het CellSearch systeem verzamelt naast circulerende tumorcellen ook circulerende 
tumorfragmenten (CTF)/tumorcel clusters (TCC)/circulerende tumoremboli (CTE) uit het bloed. 
Volgens het CelSearch systeem wordt een tumorcel cluster gedefinieerd als een groep van 
CTC met drie of meer cellen die EpCAM (Epithelial Cell Adhesion Molecule) en cytokeratinen 
tot expressie brengen, geen expressie van CD45 tonen en kernen hebben die aankleuren met 
4’6-diamino-2-phenylindole. Er zijn verschillende theorieën over hoe de TCC tot stand komen; 
een van deze is dat de TCC afbrokkelen van een tumor trombus in een bloedvat, een andere is 
dat de CTC aggregeren in de vaten als ze in de circulatie terechtkomen, en volgens een recentere 
theorie komen de TCC van oligoklonale groepen van tumorcellen en niet door intravasculaire 
aggregatie.
De samenstelling van de CTC, ctDNA en TCC verschilt onderling  en elk heeft een eigen voordeel/
nadeel met betrekking tot het verzamelen en de prognostische/voorspellende waarden. Alle drie 
kunnen verzameld worden in bloed monsters en maar hele kleine hoeveelheden zijn nodig om 
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een moleculaire studie te verrichten (het ctDNA bijvoorbeeld representeert vaak <1% van het 
totale circulerende cel-vrij DNA). De CTC en het ctDNA komt frequent voor in de circulatie en 
hebben een langere halfwaardetijd in vergelijking met TCC. Herhaaldelijke metingen van CTC 
en ctDNA zijn nodig om de patiënten te monitoren voor de progressie van de tumor en de 
resistentie voor de behandeling. Indien de genetische achtergrond van een tumor bekend is, 
kan het verzamelen van CTC of ctDNA uit het perifere bloed met een ander genetisch profiel 
informatie geven over nog niet gedetecteerde kleine klonen in de primaire tumor of een zich 
ontwikkelende of al gemetastaseerde ziekte met een ander genetisch profiel dan de primaire 
tumor. Hoge baseline metingen van CTC of ctDNA in het perifere bloed tijdens de behandeling 
zouden indicatief kunnen zijn voor resistentie tegen de therapie. In dit geval kan de therapie 
veranderd worden aan de hand van de genetische profilering van de CTC of het ctDNA. 
De TCC bevatten naast de tumorcellen ook de stromale cellen tussen de tumorcellen. De eerste 
verslaglegging over de TCC dateert uit 1950. Later werd hun schaarste in de circulatie maar de 
opmerkelijk toegenomen metastatische potentie herhaaldelijk gerapporteerd. In de recente jaren 
worden CTF/CTE/TCC geïdentificeerd naast de CTC in de studies over de epitheliale tumoren.
De TCC hebben een bewezen prognostische/voorspellende waarde, met name in de ccRCC 
patiënten.  Het is moeilijk om het gebruik van TCC te implementeren in de standaard zorg vanwege 
de kortere tijd die ze aanwezig zijn in de circulatie en de moeilijkheden om ze te verzamelen uit 
het bloed. Het merendeels ontbreken van Epcam in het oppervlak van het ccRCC maakt het 
problematisch om het CellSearch systeem te gebruiken voor het ccRCC. Echter, het aanpassen van 
het CellSearch Systeem door gebruik te maken van anti-CAIX antilichaam (Carbonic Anhydrase 
IX, bijvoorbeeld) dat een cel oppervlakte molecuul met een hoge expressie in bijna alle ccRCC 
herkent, kan een alternatieve manier van het gebruik zijn van een bekende, bewezen methodiek. 
Met de implementatie van de perfusie technieken op het resectiepreparaat zoals degene die we 
beschreven hebben in dit proefschrift die gebaseerd is op een bepaald celgrootte, kan zorgen 
voor een extra prognostische/voorspellende informatie. Als er al gemetastaseerde ziekte is ten 
tijde van de nefrectomie, kan de genetische profiling van de TCC helpen om een keuze te maken 
voor het behandelingsplan.
De gepersonaliseerde behandeling van het ccRCC kan helpen in het verkleinen van de tumor en 
het kan ook de progressie vrije overleving significant verlengen, echter het effect op de overleving 
is beperkt.  Recente studies richten zich op nieuwe doelen zoals de Hypoxia Inducible Factor 
(1α, 1β of 2α). Monoklonale antilichamen tegen CAIX proberen het ccRCC vanaf verschillende 
hoeken te attaqueren. Opkomende data over de verschillen tussen de metabole kenmerken 
van het ccRCC en de metastasen openen een hele reeks van mogelijke doelen voor nieuwe 
behandelingen. Door het gebruik van de hoog geavanceerde moleculaire methoden worden 
steeds meer medicamenteus behandelbare doelen geïdentificeerd in de primaire tumoren en de 
metastatische laesies.
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Beste Egbert,
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Beste mede authors van de afdeling urologie, oncologie, radiologie en pathologie,
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Beste Mijke,
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deed. Je bent mijn goede collega en vriendin in al deze jaren. Nu steun je me ook als mijn 
paranimf. Dank voor alles.
Beste Annette en Johan,
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onderzoeksperiode. Echte vrienden zijn zeldzaam. 
Beste Kees,
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Beste Jale,
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